WO2021234383A1 - Anticorps à domaine unique contre hace2 et leur utilisation pour prévenir une infection par sars-cov-2 - Google Patents
Anticorps à domaine unique contre hace2 et leur utilisation pour prévenir une infection par sars-cov-2 Download PDFInfo
- Publication number
- WO2021234383A1 WO2021234383A1 PCT/GB2021/051209 GB2021051209W WO2021234383A1 WO 2021234383 A1 WO2021234383 A1 WO 2021234383A1 GB 2021051209 W GB2021051209 W GB 2021051209W WO 2021234383 A1 WO2021234383 A1 WO 2021234383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- domain
- antigen
- polypeptide
- hace2
- binding domain
- Prior art date
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims description 11
- 208000025721 COVID-19 Diseases 0.000 title description 25
- 208000037847 SARS-CoV-2-infection Diseases 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 195
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 179
- 229920001184 polypeptide Polymers 0.000 claims abstract description 170
- 241000711573 Coronaviridae Species 0.000 claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 48
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 36
- 239000013598 vector Substances 0.000 claims abstract description 27
- 230000027455 binding Effects 0.000 claims description 209
- 239000000427 antigen Substances 0.000 claims description 143
- 102000036639 antigens Human genes 0.000 claims description 143
- 108091007433 antigens Proteins 0.000 claims description 143
- 241001678559 COVID-19 virus Species 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 102000009027 Albumins Human genes 0.000 claims description 49
- 108010088751 Albumins Proteins 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- 102100031673 Corneodesmosin Human genes 0.000 claims description 43
- 101710139375 Corneodesmosin Proteins 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 208000015181 infectious disease Diseases 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 27
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 25
- 230000002255 enzymatic effect Effects 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000003472 neutralizing effect Effects 0.000 claims description 9
- 108090000901 Transferrin Proteins 0.000 claims description 7
- 102000004338 Transferrin Human genes 0.000 claims description 7
- 239000012581 transferrin Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 101000773743 Homo sapiens Angiotensin-converting enzyme Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000003827 glycol group Chemical group 0.000 claims description 3
- 238000011102 hetero oligomerization reaction Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000737 potassium alginate Substances 0.000 claims description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 6
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 118
- 102000048657 human ACE2 Human genes 0.000 description 115
- 210000004027 cell Anatomy 0.000 description 91
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 53
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 53
- 235000001014 amino acid Nutrition 0.000 description 34
- 229940024606 amino acid Drugs 0.000 description 33
- 102000037865 fusion proteins Human genes 0.000 description 26
- 108020001507 fusion proteins Proteins 0.000 description 26
- 238000003776 cleavage reaction Methods 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 230000007017 scission Effects 0.000 description 25
- 241000315672 SARS coronavirus Species 0.000 description 24
- 241000700605 Viruses Species 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 17
- 230000000903 blocking effect Effects 0.000 description 15
- 230000004927 fusion Effects 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 230000003197 catalytic effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 9
- 102220599672 Spindlin-1_D614G_mutation Human genes 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 102000047200 Collagen Type XVIII Human genes 0.000 description 8
- 108010001463 Collagen Type XVIII Proteins 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 229940096437 Protein S Drugs 0.000 description 8
- 102220592182 Spindlin-1_A222V_mutation Human genes 0.000 description 8
- 102220599655 Spindlin-1_S477N_mutation Human genes 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 7
- 241000494545 Cordyline virus 2 Species 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000013638 trimer Substances 0.000 description 7
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 6
- 235000002198 Annona diversifolia Nutrition 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000036454 renin-angiotensin system Effects 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 238000005829 trimerization reaction Methods 0.000 description 6
- 241000482741 Human coronavirus NL63 Species 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 101710198474 Spike protein Proteins 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011033 desalting Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 244000303258 Annona diversifolia Species 0.000 description 4
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 4
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 102220562703 Protein Tob2_L234A_mutation Human genes 0.000 description 4
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000007502 viral entry Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000008904 Betacoronavirus Species 0.000 description 3
- 241000710190 Cardiovirus Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000711467 Human coronavirus 229E Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 241000711466 Murine hepatitis virus Species 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- 102000014022 A Kinase Anchor Proteins Human genes 0.000 description 2
- 108010011122 A Kinase Anchor Proteins Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 2
- 101710183938 Barstar Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710189104 Fibritin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 238000001327 Förster resonance energy transfer Methods 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
- 101000598058 Homo sapiens Transmembrane protease serine 11D Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 102000010638 Kinesin Human genes 0.000 description 2
- 108010063296 Kinesin Proteins 0.000 description 2
- 102220516587 Kynurenine-oxoglutarate transaminase 1_T256E_mutation Human genes 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 102100032880 Serine-rich coiled-coil domain-containing protein 1 Human genes 0.000 description 2
- 108050002465 Serine-rich coiled-coil domain-containing protein 1 Proteins 0.000 description 2
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108010033706 glycylserine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000014108 human airway trypsin-like protease Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 108010022177 mannose binding protein A Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000004896 polypeptide structure Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 102200056390 rs12204826 Human genes 0.000 description 2
- 102200128238 rs201124247 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241001521805 Aeletes Species 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 101150044980 Akap1 gene Proteins 0.000 description 1
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101710199744 Anionic trypsin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100031024 CCR4-NOT transcription complex subunit 1 Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 1
- 101000614502 Caenorhabditis elegans Adenylate kinase isoenzyme 6 homolog Proteins 0.000 description 1
- 101000919674 Caenorhabditis elegans CCR4-NOT transcription complex subunit let-711 Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102220585969 Claspin_S982A_mutation Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- 101000919672 Homo sapiens CCR4-NOT transcription complex subunit 1 Proteins 0.000 description 1
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102220622573 Inositol-tetrakisphosphate 1-kinase_N297L_mutation Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102220476512 Interleukin-18 receptor 1_N297Q_mutation Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102220558850 Lysosome-associated membrane glycoprotein 2_V264A_mutation Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 102220637955 Nuclear receptor ROR-alpha_A330L_mutation Human genes 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- 101800001332 Processed angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102400000589 Processed angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 102220479472 Proteasome inhibitor PI31 subunit_F241A_mutation Human genes 0.000 description 1
- 101800001065 Protein 2B Proteins 0.000 description 1
- 102220486066 Protein YAE1 homolog_D265A_mutation Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102220497450 Putative cytochrome P450 family member 4F30_G237A_mutation Human genes 0.000 description 1
- 102220469840 Putative high mobility group protein B1-like 1_D270A_mutation Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108091006367 SARS-CoV-2 Spike Subunit S2 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001417517 Scatophagidae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710151381 Serine protease 2 Proteins 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- 102220599400 Spindlin-1_D1118H_mutation Human genes 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 1
- 102220599630 Spindlin-1_T1027I_mutation Human genes 0.000 description 1
- 102220590630 Spindlin-1_T20N_mutation Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102220510809 Toll-like receptor 3_P681H_mutation Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102100034392 Trypsin-2 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102220532017 WW domain-binding protein 11_K322A_mutation Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000001286 analytical centrifugation Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010378 bimolecular fluorescence complementation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004193 electrokinetic chromatography Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000049800 human TMPRSS2 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 102200161309 rs121908332 Human genes 0.000 description 1
- 102220053319 rs139287714 Human genes 0.000 description 1
- 102200110414 rs151344489 Human genes 0.000 description 1
- 102220277108 rs1553412687 Human genes 0.000 description 1
- 102220272292 rs1555605079 Human genes 0.000 description 1
- 102220331416 rs1557007136 Human genes 0.000 description 1
- 102220053106 rs199537178 Human genes 0.000 description 1
- 102220046580 rs201314910 Human genes 0.000 description 1
- 102200144284 rs235768 Human genes 0.000 description 1
- 102220075059 rs529697285 Human genes 0.000 description 1
- 102220078383 rs572958701 Human genes 0.000 description 1
- 102220046286 rs587782805 Human genes 0.000 description 1
- 102220046912 rs61751448 Human genes 0.000 description 1
- 102220033185 rs62646881 Human genes 0.000 description 1
- 102220177056 rs763780768 Human genes 0.000 description 1
- 102220235568 rs768967856 Human genes 0.000 description 1
- 102220058675 rs786203529 Human genes 0.000 description 1
- 102220029076 rs78775072 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010381 tandem affinity purification Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 244000000023 zoonotic pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention relates to molecules with therapeutic activity against a coronavirus infection.
- SARS-CoV-2 is currently considered a pandemic infection involving 190 countries, with more than 150 million confirmed cases and more than 3.2 million confirmed deaths worldwide, as of 4 th May 2020.
- Trials are currently ongoing for the antiviral reagents Remdesivir (Gilead), Chloroquine and hydroxychloroquine, and Ritonavir/Lopinavir (Kaletra, Abb Vie).
- Remdesivir Remdesivir
- Chloroquine and hydroxychloroquine Chloroquine and hydroxychloroquine
- Ritonavir/Lopinavir Kerattra, Abb Vie
- Other companies such as EliLilly/ AbCeller, Takeda, and Regeneron have also announced intentions to test cocktails of neutralising antibodies, while more than 35 vaccine strategies are currently being investigated.
- Presently, no specific anti-viral treatment has been approved.
- SARS-CoV-2 has been shown to bind to angiotensin-converting enzyme 2 (ACE2) via the spike protein (S protein) on its surface ( Figure 1 A).
- ACE2 angiotensin-converting enzyme 2
- Figure 1 A spike protein
- Lei at al. described a recombinant ACE2-Fc fusion protein able to neutralize SARS-CoV-2 (Lei et al., 2020, bioRxiv 2020.02.01.929976; https://doi.org/10.1101/2020.02.01.929976).
- a similar construct was also effective against SARS-CoV in 2003 (Moore et al., 2004, J Virol 78:10628-35).
- non-neutralizing antibodies to variable S domains may enable an alternative infection pathway via Fc receptor-mediated uptake.
- These antibodies can act to enhance viral infection by aiding viral entry into cells which don’t express the target receptor. This mechanism of improved virus uptake, termed antibody-dependent enhancement (ADE) of infection.
- AD antibody-dependent enhancement
- the present inventors have generated a series of antiviral agents with ability to block infection by coronaviruses, and SARS-CoV and SARS-CoV-2 in particular. These molecules are based on antibodies that are specific for ACE2 that have been fused to serum half-life extending moieties. The ability of these molecules to block coronavirus virions entry into host cells is increased by combining antibodies to different epitopes on ACE2. Through stronger interactions with the ACE2 receptor, the inefficient neutralisation capacity of previous targeting approaches is improved. Furthermore, these fusion proteins do not interfere with the catalytic activity of ACE2 and thus do not interfere with its key role in maintaining blood pressure via the Renin- Angiotensin System (RAS).
- RAS Renin- Angiotensin System
- Targeting ACE2 is also advantageous because the host receptor does not change and thus viral escape from binding the therapeutic agent is prevented. Moreover, if the binding site for the virus is occluded the virus will not have the ability to mutate and bind an entirely new host receptor in the time frame of the current SARS-CoV-2 outbreak.
- the present invention provides a polypeptide comprising: a) an antigen-binding domain that binds specifically to the human angiotensin converting enzyme type 2 (hACE2) ectodomain; and b) a half-life extending domain.
- hACE2 human angiotensin converting enzyme type 2
- the antigen-binding domain and the half-life extending domain may be joined by a linker.
- the polypeptide may further comprise at least one additional antigen-binding domain that binds specifically to the hACE2 ectodomain, wherein the antigen-binding domain and the at least one additional antigen-binding domain bind to different epitopes of the hACE2 ectodomain.
- the antigen-binding domain and/or the at least one additional antigen-binding domain, where present, may compete with a coronavirus spike protein (S protein) for binding to hACE2.
- S protein coronavirus spike protein
- the binding of the antigen-binding domain and the at least one additional antigen-binding domain, where present, to hACE2 may not inhibit its enzymatic activity.
- the antigen-binding domain and the at least one additional antigen-binding domain, where present, may bind to an epitope in hACE2 which does not comprise one or more of amino acids R169, R273, H345, P346, T371, H374, Q375, H378, E402, W477, K481, H505, or Y515 of the sequence shown as SEQ ID NO: 1.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may bind to the cell-bound hACE2 ectodomain.
- the antigen-binding domain and the at least one additional antigen-binding domain, where present, may comprise the CDR1, CDR2, and CDR3 from one of the sequences shown as SEQ ID NO: 5-11 or 50-97.
- the antigen-binding domain and the at least one additional antigen-binding domain, where present, are selected from a scFv or a domain antibody selected from a VH or a dAb, or a single-domain antibody (sdAb), or a VHH or a nanobody.
- the half-life extending domain is selected from albumin, or an albumin domain, or an antigen-binding domain that binds specifically to albumin, or an albumin-binding-peptide, or an albumin-binding domain of a Streptococcus protein, or transferrin, or a hetero oligomerization domain, or a polyethylene glycol moiety.
- the present invention provides a nucleic acid encoding the polypeptide according to the first aspect of the invention.
- the present invention provides an expression cassette comprising the nucleic acid according to the second aspect of the invention.
- the present invention provides a vector comprising the nucleic acid according to the second aspect of the invention or the expression cassette according to the third aspect of the invention.
- the present invention provides a cell comprising the nucleic acid according to the second aspect of the invention, or the expression cassette according to the third aspect of the invention, or the vector according to the fourth aspect of the invention.
- the present invention provides a method for making a polypeptide according to the first aspect of the invention by culturing a cell according to the fifth aspect of the invention and purifying the polypeptide from the supernatant.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the polypeptide according to the first aspect of the invention and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
- the present invention provides a polypeptide according to the first aspect of the invention, or a pharmaceutical composition according to the seventh aspect of the invention for use in medicine.
- the present invention provides a polypeptide according the first aspect of the invention, or a pharmaceutical composition according to the seventh aspect of the invention for use in the treatment of a coronavirus infection or a condition or disorder resulting from this infection.
- the present invention provides a use of a polypeptide according to the first aspect of the invention, or a pharmaceutical composition according to the seventh aspect of the invention in the manufacturing of a medicament for the treatment of a coronavirus infection or a condition or disorder resulting from this infection.
- the present invention provides a method for treating a coronavirus infection or a condition or disorder resulting from this infection in a subject in need thereof comprising a step of administering a polypeptide according to the first aspect of the invention, or a pharmaceutical composition according to the seventh aspect of the invention to the subject.
- the present invention provides a method of neutralising a coronavirus infection, comprising a step of contacting a polypeptide according to the first aspect of the invention or a pharmaceutical composition according to the seventh aspect of the invention with a cell expressing hACE2.
- the coronavirus in the ninth, tenth, eleventh, or twelfth aspects of the invention may be SARS-CoV-2.
- FIG. 1 A. X-ray crystal structure of the ACE2-S1 complex.
- FIG. 1 Half-life extended anti ACE2 fusion constructs.
- Figure 3 Schematic of naive llama library display. Potential hits identified are shown in right hand box.
- Figure 4 Characterisation of the binding specificity of dAbs specific for the human ACE2 protein. Black bars show binding to human ACE2; white bars show non-specific binding control to unrelated B7H3 peptides; grey bars show non-specific binding to milk.
- VHH-Fc-MuIgG2a Fc Individual anti-ACE2 dAb
- VHH-Fc format VHH-MuIgG2a Fc
- ELISA ELISA-Fc-coated wells. Bars show binding of SARS-CoV2 SI protein to human ACE2.
- VHH Blocking activity of three dAb (VHH) clones shown as the percentage of binding of SARS-CoV2 SI protein to hACE2, relative to no antibody condition (Baseline - no SI - subtracted).
- FIG. 1 ACE2 enzymatic activity in the presence of anti-ACE2 dAbs (VHH).
- the present invention provides recombinant fusion proteins which have the ability to block viral entry of coronavirus, and SARS-CoV-2 virus in particular, and viral re-entry. These fusion proteins are based on antibodies binding to ACE2. 1. Coronavirus
- SARS-CoV severe acute respiratory syndrome coronavirus
- MERS-CoV Middle East respiratory syndrome coronavirus
- SARS-CoV-2 SARS- CoV-2.
- SARS-CoV a lineage B beta-CoV, emerged from bat and palm civet, and infected over 8,000 people and caused about 800 deaths.
- MERS-CoV a lineage C beta-CoV
- SARS-CoV-2 a novel coronavirus
- HCoV-OC43 In addition to the highly pathogenic zoonotic pathogens SARS-CoV, MERS-CoV, and SARS-CoV-2, all belonging to the b-coronavirus genus, four low-pathogenicity coronaviruses are endemic in humans: HCoV-OC43, HCoV-HKUl, HCoV-NL63, and HCoV-229E.
- coronaviruses are a diverse group of large RNA viruses that cause varieties of diseases in humans and other animals, including respiratory, enteric, renal, and neurological diseases.
- Coronaviruses are enveloped viruses that contain a large single-stranded RNA genome of positive polarity. At ⁇ 30,000 nucleotides (nt), their genome is the largest found in any of the RNA viruses.
- Their envelope accommodates three or four membrane proteins of which the membrane (M), envelope (E), and spike (S) proteins are common to all.
- the S protein is a relatively large, about 180kDa type I glycoprotein, turners of which form the petal-shaped projections on the surface of the virion that give rise to the characteristic corona solis-like appearance. It has been suggested that the SI subunit constitutes the globular head, while the S2 subunit forms the stalk-like region of the spike.
- the two functions of the coronavirus S protein appear to be spatially separated.
- the SI subunit (or the equivalent part in viruses with uncleaved S protein) is responsible for receptor binding, and the S2 subunit is responsible for membrane fusion.
- NTD N-terminal domain
- C-domain C-terminal domain
- RBD receptor-binding domain
- MHV uses mouse carcinoembryonic antigen related cell adhesion molecule la (mCEACAMla) as the receptor, and the receptors for SARS-CoV and MERS- CoV are human angiotensin-converting enzyme 2 (hACE2) and dipeptidyl peptidase 4 (DPP4), respectively.
- hACE2 human angiotensin-converting enzyme 2
- DPP4 dipeptidyl peptidase 4
- S proteins of SARS-CoV-2 share about 76% and 97% of amino acid identity with SARS-CoV and RaTG13, respectively, and the amino acid sequence of potential RBD of SARS-CoV-2 is about 74% and 90.1% homologous to that of SARS-CoV and RaTG13, respectively.
- the ectodomain of the S2 subunit contains two heptad repeat (HR) regions, HRl and HR2, characteristic of coiled coils, while the fusion peptide (FP) is predicted to be located amino terminally of the first HR region (HRl).
- HR heptad repeat
- FP fusion peptide
- Binding of the SI subunit to the (soluble) receptor has been shown to trigger conformational changes that supposedly facilitate virus entry by activation of the fusion function of the S2 subunit.
- the conformational changes are thought to expose the fusion peptide and to lead to the formation of a heterotrimeric six-helix bundle by the two HR regions, a characteristic of class I viral fusion proteins, resulting in the close locations of the fusion peptide and the transmembrane domain in the process of membrane fusion.
- Coronavirus S proteins are typical class I viral fusion proteins, and protease cleavage is required for activation of the fusion potential of S protein.
- a two-step sequential protease cleavage model has been proposed for activation of S proteins of SARS-CoV and MERS- CoV, priming cleavage between SI and S2 and activating cleavage on S2’ site.
- CoV S proteins may be cleaved by one or several host proteases, including furin, trypsin, cathepsins, transmembrane protease serine protease-2 (TMPRSS-2), TMPRSS-4, or human airway trypsin-like protease (HAT).
- SARS-CoV-2 S protein is capable of triggering protease-independent and receptor-dependent syncytium formation. Such a mechanism might enhance virus spreading through cell-cell fusion and this might partially explain rapid progress of the disease.
- the coronavirus may be one of the following coronaviruses: SARS-CoV-2, SARS-CoV, SARS-like CoV RaTG13, MERS-CoV, HCoV-OC43, HCoV-HKUl, HCoV-NL63, and HCoV-229E.
- the coronavirus may be selected from SARS-CoV-2, SARS-CoV or SARS-like CoV RaTG13.
- the coronavirus may be SARS-CoV-2.
- the coronavirus S protein may be the S protein of one of the following coronavirus: SARS- CoV-2, SARS-CoV, SARS-like CoV RaTG13, MERS-CoV, HCoV-OC43, HCoV-HKUl, HCoV-NL63, and HCoV-229E.
- the coronavirus S protein may be the S protein of SARS-CoV-2, SARS-CoV, or SARS-like CoV RaTG13.
- the coronavirus S protein may be the S protein of SARS-CoV-2
- the coronavirus S protein may be the S protein of SARS-CoV-2 depicted under Uniprot accession number P0DTC2 (sequence version 1, as of 22 nd April 2020).
- SARS-CoV-2 S protein SEQ ID NO: 2; signal sequence underlined), subunit SI (SEQ ID NO: 3) and subunit S2 (SEQ ID NO: 4; HR1 region is underlined and HR2 region is in bold) of coronavirus SARS-CoV-2 are shown below.
- SARS-CoV-2 S protein SEQ ID NO: 2; signal sequence underlined, subunit SI (SEQ ID NO: 3) and subunit S2 (SEQ ID NO: 4; HR1 region is underlined and HR2 region is in bold) of coronavirus SARS-CoV-2 are shown below.
- SARS-CoV-2 S protein SEQ ID NO: 2; signal sequence underlined), subunit SI (SEQ ID NO: 3) and subunit S2 (SEQ ID NO: 4; HR1 region is underlined and HR2 region is in bold) of coronavirus SARS-CoV-2 are shown below.
- SARS-CoV-2 S protein SEQ ID NO: 2; signal sequence underlined
- VFLVLLPLV SOC VNLTTRTOLPPAYTN SFTRGVYYPDKVFRS S VLHSTODLFL PFF SNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYF ASTEKSNIIRGWIF GTTLDSK TQSLLIVNNATNVVIKVCEF QF CNDPFLGVYYHKNNKSWMESEFRVY S S ANNCTF EYVSQPFLMDLEGKQGNFKNLREF VFKNIDGYFKIY SKHTPINLVRDLPQGF SALE PLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPF GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFT NVY AD SF VIRGDEVRQIAPGQ
- SARS-CoV-2 Spike protein SI subunit (SEQ ID NO: 3):
- SARS-CoV-2 Spike protein S2 subunit (SEQ ID NO: 4):
- the coronavirus may be SARS-CoV-2.
- the SARS-CoV-2 coronavirus may have the S protein of wild type SARS-CoV-2 (SEQ ID NO: 1) or a variant thereof having one or more mutations from the sequence shown as SEQ ID NO: 2.
- Variants of one the S protein of wild type SARS-CoV-2 include, without limitation, variants D614G; A222V; S477N; clade 20B/501Y.V1 or UK variant B.1.1.7; clade 20C/501Y.V2, B.1.351 or South African variant; Brazilian variants B.1.1.28, P.l and P.2; Indian variants B.1.617, B.1.617.1, B.1.617.2 and B.1.617.3; variants B.1.526 and B.1.526.1.
- Variants of wild type SARS-CoV-2 include, without limitation, variants D614G; A222V; S477N; clade 20B/501Y.V1 or UK variant B.l.1.7; and clade 20C/501Y.V2, B.1.351 or South African variant; Brazilian variant B.1.1.28, P.l and P.2; Indian variants B.1.617, B.1.617.1, B.1.617.2 and B.1.617.3; variants B.1.526 and B.1.526.1.
- the present invention is useful with any other SARS- CoV-2 variants existent at the time of filing or with any future variants that may emerge, as well as any other coronaviruses that use ACE2 as a receptor to infect cells.
- the coronavirus S protein may be the S protein of any of these variants.
- the present invention provides a polypeptide, hereinafter “the polypeptide of the invention” comprising: a) an antigen-binding domain that binds specifically to the human angiotensin converting enzyme type 2 (hACE2) ectodomain, and b) a half-life extending domain.
- the term polypeptide, as used herein, refers to natural, synthetic, and recombinant proteins or peptides generally having more than 10 amino acids.
- the polypeptide of the invention comprises an antigen-binding domain that binds specifically to the human angiotensin converting enzyme type 2 (hACE2) ectodomain.
- hACE2 human angiotensin converting enzyme type 2
- angiotensin converting enzyme type 2 Human ACE2 is depicted under Accession No. Q9BYF1 in the Uniprot database on 30 th March 2020.
- hACE2 is an 805 aa transmembrane protein with a processed ectodomain that spans aa 18-740 of the sequence shown under Uniprot Accession No. Q9BYF1.
- Q9B YF 1 in the Uniprot database on 30 th March 2020 is shown as SEQ ID NO: 42.
- the leader peptide spans aa 1-17
- the processed ectodomain spans aa 18-740
- the transmembrane domain spans aa 741-761
- the cytoplasmic domain spans 762-805.
- Human ACE2 has been identified as a functional receptor for the S protein of human coronavirus NL63 (HCoV-NL63) and of SARS coronavirus (SARS-CoV). More recently, it has also been shown to be a receptor for SARS-CoV-2.
- the epitopes on hACE2 that are recognised by the S protein have been reported to comprise one or more of the regions corresponding to positions 19-41, 82-84 and 353-357 of the full ACE2 ectodomain (SEQ ID NO: 1).
- ACE2 is a metalloprotease involved in the Renin- Angiotensin System (RAS), which controls blood pressure, electrolytes and intravascular fluid volume.
- RAS Renin- Angiotensin System
- a key function of hACE2 is believed to be the cleavage of Angiotensin II (Ang II) to Ang (1-7), which have opposing physiological roles. Elevated levels of Ang II are associated with vasoconstriction, inflammation, fibrosis, vascular leak, and sodium absorption.
- Ang (1-7) appears to be a counterregulatory protein in the RAS; associated with vasodilation, anti-proliferation, antiinflammation, and reduced vascular leak.
- hACE2 has also been reported to have a protective role in acute lung injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections.
- hACE2 In a normal adult human lung, hACE2 is expressed primarily in alveolar epithelial type II cells, which can serve as a viral reservoir. These cells produce surfactant which reduces surface tension, thus preventing alveoli from collapsing, and hence are critical to the gas exchange function of the lung. Damage to these cells could explain the severe lung injury observed in COVID-19 patients. hACE2 is also expressed in multiple extrapulmonary tissues including heart, kidneys, blood vessels, and intestine. The ACE2 tissue distribution in these organs may explain the multiorgan dysfunction observed in patients. There have been reports of patients presenting pulmonary embolism and kidney damage, probably caused by blood clots damaging the pulmonary and renal capillaries, as well as myocarditis, increased blood pressure, abdominal pain, diarrhoea and nausea.
- antigen-binding domain refers to a polypeptide having an antigen binding site which comprises at least one complementarity determining region or CDR.
- the antigen-binding domain may comprise 3 CDRs and have an antigen binding site which is equivalent to that of a single domain antibody (dAb), heavy chain antibody (VHH) or a nanobody.
- the antigen-binding domain may comprise 6 CDRs and have an antigen binding site which is equivalent to that of a classical antibody molecule.
- the remainder of the polypeptide may be any sequence which provides a suitable scaffold for the antigen binding site and displays it in an appropriate manner for it to bind the antigen.
- a full-length antibody or immunoglobulin typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide.
- Each of the heavy chains contains one N terminal variable (VH) region and three C-terminal constant (CHi, CEE and CEE) regions, and each light chain contains one N- terminal variable (VL) region and one C-terminal constant (CL) region.
- the variable regions of each pair of light and heavy chains form the antigen binding site of an antibody.
- CDR complementarity determining regions
- the CDRs of the two chains of each pair are aligned by the framework regions, acquiring the function of binding a specific epitope. Consequently, in the case of VH and VL domains both the heavy chain and the light chain are characterised by three CDRs, respectively CDRH1, CDRH2, CDRH3 and CDRLl, CDRL2, CDRL3.
- CDR-IMGT complementarity determining region
- CDR1-IMGT loop BC
- CDR2- IMGT loop C'C
- CDR3-IMGT loop FG
- Other definitions of the CDRs have also been developed, such as the Chothia, the AbM and the contact definitions (see http://www.imgt.org). Unless stated otherwise, the CDRs described herein are derived using the IMGT system.
- antibody fragment and “antigen-binding portion” are used interchangeably herein and refer to one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen.
- the antibody fragment may comprise, for example, one or more CDRs, the variable region (or portions thereof), the constant region (or portions thereof), or combinations thereof.
- antibody fragments include, but are not limited to, a Fab fragment, a F(ab’)2 fragment, an Fv fragment, a single chain Fv (scFv), or a domain antibody [VH or dAb, single domain antibody (sdAb), VHH, and nanobody].
- the antigen-binding domain may be selected from a scFv or a domain antibody selected from a VH or a dAb, single domain antibody (sdAb), VHH, or nanobody.
- VH refers to the variable heavy domain of an IgG.
- VHH or “dAb” or “sdAb” or “nanobody” refers to the variable domain (single domain) of a camelid antibody.
- the antigen-binding domain of the polypeptide of the invention may comprise an antigenbinding domain which is based on a non-immunoglobulin scaffold, also known as antibody mimetic. These antibody-binding domains are also called antibody mimetics.
- Non-limiting examples of non-immunoglobulin antigen-binding domains include an affibody, a fibronectin artificial antibody scaffold, an anticalin, an affilin, a DARPin, a VNAR, an iBody, an affimer, a fynomeran, abdurin/nanoantibody, a centyrin, an alphabody, a nanofitin, and a D domain.
- the antigen-binding domain may be non-human, such as murine, rat or camelid, chimeric, humanised or fully human.
- the antigen-binding domain may be synthetic.
- Antibodies may be obtained from animal serum, or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or mammalian cell culture.
- monoclonal antibodies are typically made by fusing myeloma cells with the spleen cells from a mouse or rabbit that has been immunised with the desired antigen.
- the desired antigen is the ectodomain of hACE2 or a peptide thereof.
- the antigen-binding domain will be readily obtained from monoclonal antibodies by means of molecular biology techniques that are conventional in the art.
- antibodies and related molecules may be made outside the immune system by combining libraries of VH and VL chains in a recombinant manner.
- Libraries of VH or VHH, or dAb, or sdAb or nanobodies may also be generated. Such libraries may be constructed and screened using phage-display technology as described in Example 1.
- the antibody libraries may be immune or non-immune.
- Antibodies which are selective for hACE2 or a peptide thereof may be identified using methods which are standard in the art.
- Methods for determining the binding specificity of an antibody include, but are not limited to, enzyme-linked immunosorbent assay (ELISA), and competitive ELISA, western blot, immunofluorescent techniques such as immunohistochemistry (IHC), fluorescence microscopy, and flow cytometry; surface plasmon resonance (SPR), radioimmunoassay (RIA), Forster resonance energy transfer (FRET), phage display libraries, yeast two-hybrid screens, co-immunoprecipitation, bimolecular fluorescence complementation and tandem affinity purification.
- ELISA enzyme-linked immunosorbent assay
- competitive ELISA western blot
- immunofluorescent techniques such as immunohistochemistry (IHC), fluorescence microscopy, and flow cytometry
- SPR surface plasmon resonance
- RIA radioimmunoassay
- FRET Forster resonance energy
- the infectivity neutralisation ability of antibodies may be determined by incubating the antibodies with relevant virus, e.g. lentiviral vectors pseudotyped with coronavirus S protein, and cultured onto ACE2-expressing cells. These methods are further described in Example 3.
- relevant virus e.g. lentiviral vectors pseudotyped with coronavirus S protein
- coronaviruses have high mutation rates, some of them in the S protein which may translate in stronger interactions with hACE2. Binding to different epitopes on hACE2 is advantageous for blocking the interaction of the S protein more efficiently. This may in turn also prevent viral entry.
- the polypeptide of the invention may further comprise at least one additional antigen binding domain that binds specifically to the hACE2 ectodomain, wherein the antigen binding domain and the at least one additional antigen-binding domains bind to different epitopes of the hACE2 ectodomain.
- the polypeptide of the invention may have two, three, or more antigen-binding domains, each binding to a different epitope of the hACE2 ectodomain.
- the two or more antigen-binding domains may be fused to the half-life extending domain in tandem. Where the half-life extending domain is a hetero-oligomer, each of the two or more antigen-binding domains may be fused to a different monomer.
- the antigen binding domain and/or the at least one additional antigen-binding domain, where present, may compete with a coronavirus S protein for binding to hACE2.
- Competition for the binding site on hACE2 may be direct by binding to the same or to an overlapping epitope. Competition may also be achieved by steric hindrance when the epitope recognised by the binding antigen(s) is not the same as the one recognised by the S protein. Both types of competition may be achieved when the polypeptide of the invention comprises two or more antigen-binding domains, each binding to a different epitope of the hACE2 ectodomain.
- hACE2 has a key role in the Renin-Angiotensin System (RAS), as previously explained, the binding of the antigen-binding domain and, where present, the at least one additional antigen-binding domain, to hACE2 may not inhibit its enzymatic activity. In other words, the ability of hACE2 to cleave Ang II to Ang (1-7) may not be prevented or inhibited by binding of the one, two or more antigen-binding domains to hACE2. Other functions of hACE2 that may be later discovered may also not be prevented or inhibited.
- RAS Renin-Angiotensin System
- the antigen binding domain and/or, where present, the at least one additional antigen binding domain may not inhibit the catalytic activity of hACE2 compared to that of wild- type hACE2.
- the catalytic or enzymatic activity of hACE2 may be considered to be inhibited when it is less than 80%, or 70%, or 60%, or 50%, or lower of the catalytic activity of hACE2 in the presence of a substrate and in the absence of any inhibitor.
- the antigen binding domain and/or, where present, the at least one additional antigen-binding domain may maintain, substantially maintain or increase the catalytic activity of hACE2 compared to that of wild-type hACE2.
- the catalytic or enzymatic activity of hACE2 may be considered to be maintained or substantially maintained when it is between about 80% and about 120%, or between about 90% and about 110%, or between about 95% and 105%, or about 100% of the catalytic activity of hACE2 in the presence of a substrate and in the absence of any inhibitor.
- the catalytic or enzymatic activity of hACE2 may be considered to be increased when it is more than 120%, or 130%, or 140%, or 150%, or higher of the catalytic activity of hACE2 in the presence of a substrate and in the absence of any inhibitor.
- the enzymatic or catalytic activity of hACE2 may be determined by any method available in the art.
- Non-limiting examples include methods that use chromogenic and fluorogenic substrates for ACE2, i.e. by incubating the protein with a surrogate fluorogenic substrate for ACE2, such as Mca-APK(Dnp) (Examples 3 or 6). Briefly, ACE2 activity is measured using Mca-Ala-Pro-Lys(Dnp)-OH substrate [Mca-APK(Dnp)], and a Mca control peptide is used as a negative control. Mca fluorescence is quenched by the Dnp group until cleavage by ACE2 (at Pro-Lys) separates them enabling inherent fluorescence from Mca. The fluorescence is monitored over time.
- the antigen-binding domain and the at least one additional antigen-binding domain, where present, may bind to an epitope in hACE2 which does not comprise one or more of amino acids R169, R273, H345, P346, T371, H374, Q375, H378 , E402, W477, K481, H505, or Y515 of the sequence shown as SEQ ID NO: 1.
- the present inventors have hypothesised that these residues form part of the active site and/or allosteric sites of hACE2 ( Figure IB).
- the antigen-binding domain and the at least one additional antigen-binding domain, where present, may bind to an epitope in hACE2 which comprises or consists of one or more of the following amino acid regions on SEQ ID NO: 1: amino acids 19-89, amino acids 319-340, amino acids 352-357, amino acids 386-389, and/or amino acid 393.
- Protease mediated shedding of the ectodomain of hACE2 has been reported and a soluble form of ACE2, lacking its cytosolic and transmembrane domains, has been shown to block binding of the SARS-CoV spike protein to its receptor. This may be exploited by the present antiviral approach by using binders that recognise cell-bound hACE2.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may bind to the cell-bound hACE2 ectodomain.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may comprise the CDR1, CDR2 and CDR3 of one of the sequences shown as SEQ ID NO: 5-11 and 50-97.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may comprise the CDR1, CDR2 and CDR3 of one of the sequences shown as SEQ ID NO: 81, 91 and 96.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may comprise or consist of one of the sequences shown as SEQ ID NO: 5-11 and 50-97.
- the antigen-binding domain and/or at least one additional antigen-binding domain, where present, may comprise or consist of one of the sequences shown as SEQ ID NO: 81, 91 and 96.
- V OLOE S GGGL V O AGP SLRL S C A AS GRTIS S Y AMGWFRO APGKEREF V AT STRS GGRAYYADSVKGRFTISRDNAKNTVNLOMNSLKPEDTAVYYCAATYSDSDYVIR S VHGTD Y W GKGTL VT V S
- V OLOE S GGGL V O AGGSLTL S C A V S GNRLSIGAMGW YRO APGKOREM V ATITR GGSTNYADSVKGRFTISRDNAKDTVSLOMNSLKPEDTAVYYCNAHYLISDRWGO
- V OLOE S GGGL V O AGGSLRL S C A V S GSIF S VNDMGW YRO APGREREW V ATITSG GRTNYAESVKGRFTISRDNVNKT V SLOMN SLEAEDT AVYY CDAFLRPSRGSREY VYWGQGIQVTVS
- antigen-binding domain of the polypeptide of the invention is also intended to embrace functionally equivalent variants of the antigen-binding domain, variants which have been modified in the amino acid sequence without adversely affecting, to any substantial degree, (i) its capacity to block the binding of the S protein of coronavirus to hACE2 relative to that of the parent antigen-binding domain, and/or (ii) the enzymatic activity of hACE2.
- Said modifications include the conservative (or non-conservative) substitution of one or more amino acids for other amino acids, the insertion and/or the deletion of one or more amino acids into the antigen-binding domain, provided that the capacity to interact with hACE2 of the variant is substantially maintained and/or the enzymatic activity of hACE2 is not substantially affected at physiological conditions.
- variant refers to a polypeptide differing from a specifically recited polypeptide, i.e. reference or parent polypeptide by amino acid insertions, deletions, and/or substitutions, created using, for example, recombinant DNA techniques or by de novo synthesis. Variant and mutant are used indistinctly in the context of the present invention.
- the variants or mutants of the antigen binding domain comprising one of the amino acid sequences shown as SEQ ID NO: 5-11 and 50-97 may have at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% sequence identity with the corresponding sequences shown as SEQ ID NO: 5-11 and 50-97, provided that the capacity to interact with hACE2 of the variant is substantially maintained and/or the enzymatic activity of hACE2 is not substantially affected upon binding relative to those of the parent antigen-binding domain.
- Variants of the antigen-binding domain comprising one of the amino acid sequences shown as SEQ ID NO: 5-11 and 50-97 typically have at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the corresponding sequences given as SEQ ID NO: 5-11 and 50-97.
- variants may contain one or more conservative amino acid substitutions compared to the original amino acid or nucleic acid sequence. Conservative substitutions are those substitutions that do not substantially affect or decrease the capacity to interact with hACE2 of the variant and/or the enzymatic activity of hACE2 upon binding.
- an antigen-binding domain variant that specifically binds hACE2 may include up to 1, up to 2, up to 5, up to 10, or up to 15 conservative substitutions compared to any of the sequences given as SEQ ID NO: 5-11 and 50-97 and retain capacity to interact with hACE2 of the parent antigen-binding domain and/or the enzymatic activity of hACE2 upon binding.
- Variants of the antigen-binding domain have at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the sequences given as SEQ ID NO: 5-11 and 50-97.
- amino acids which may be exchanged by way of conservative substitution are well known to one of ordinary skill in the art.
- the following six groups are examples of amino acids that are considered to be conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
- the percentage of sequence identity may be determined by comparing two optimally aligned sequences over a comparison window.
- the aligned sequences may be polynucleotide sequences or polypeptide sequences.
- the portion of the polynucleotide or amino acid sequence in the comparison window may comprise insertions or deletions (i.e., gaps) as compared to the reference sequence (that does not comprise insertions or deletions).
- the percentage of sequence identity is calculated by determining the number of positions at which the identical nucleotide residues, or the identical amino acid residues, occurs in both compared sequences to yield the number of matched positions, then dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
- Sequence identity between two polypeptide sequences or two polynucleotide sequences can be determined, for example, by using the Gap program in the WISCONSIN PACKAGE version 10.0-UNIX from Genetics Computer Group, Inc.
- the percentage of sequence identity between polypeptides and their corresponding functions may be determined, for example, using a variety of homology -based search algorithms that are available to compare a query sequence, to a protein database, including for example, BLAST, FASTA, and Smith-Waterman.
- BLASTX and BLASTP algorithms may be used to provide protein function information. A number of values are examined in order to assess the confidence of the function assignment. Useful measurements include “E-value” (also shown as “hit JD”), “percent identity”, “percent query coverage”, and “percent hit coverage”.
- the E-value, or the expectation value represents the number of different alignments with scores equivalent to or better than the raw alignment score, S, that are expected to occur in a database search by chance.
- a “high” BLASTX match is considered as having an E- value for the top BLASTX hit of less than IE-30; a medium BLASTX is considered as having an E-value of IE-30 to IE-8; and a low BLASTX is considered as having an E- value of greater than IE-8.
- Percent identity refers to the percentage of identically matched amino acid residues that exist along the length of that portion of the sequences which is aligned by the BLAST algorithm. In setting criteria for confidence of polypeptide function prediction, a “high” BLAST match is considered as having percent identity for the top BLAST hit of at least 70%; a medium percent identity value is considered from 35% to 70%; and a low percent identity is considered of less than 35%.
- Query coverage refers to the percent of the query sequence that is represented in the BLAST alignment, whereas hit coverage refers to the percent of the database entry that is represented in the BLAST alignment.
- a polypeptide of the invention is one that either (1) results in hit_p ⁇ le-30 or % identity >35% AND query _coverage>50% AND hit_coverage>50%, or (2) results in hit p ⁇ le-8 AND query _coverage>70% AND hit_coverage>70%.
- Variants of the antigen-binding domain comprising one of the amino acid sequences shown as SEQ ID NO: 5-11 and 50-97 may maintain at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the capacity to interact with hACE2 of the parent antigen-binding domain. Variants of the antigen-binding domain comprising one of the amino acid sequences shown as SEQ ID NO: 5-11 and 50-97 may have an increased capacity to interact with hACE2 of about 105%, for example at least about 110%, 115%, 120%, 125%, 130%, 140%, 150% or more compared with that of the parent molecule.
- the interaction between the antigen-binding domain or the variants thereof and hACE2 and coronavirus S protein can be determined by conventional methods. For example, the interaction may be determined by ELISA, surface plasmon resonance (SPR), or by flow cytometry using ACE2-expressing cells. Additionally, the ability of the antigen-binding domain or the variants thereof to block viral entry on hACE2-expressing cells may be determined by incubating the antigen-binding domain or the variants thereof or the polypeptide of the invention with relevant viruses, e.g. lentiviral vectors pseudotyped with coronavirus S protein, and cultured onto ACE2-expressing cells. These methods are further described in Example 3.
- relevant viruses e.g. lentiviral vectors pseudotyped with coronavirus S protein
- Variants of the antigen-binding domain comprising one of the amino acid sequences shown as SEQ ID NO: 5-11 and 50-97 may maintain at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the enzymatic activity of hACE2 upon binding to hACE2. Methods to determine the enzymatic activity of hACE2 have been described previously. 2.2. Half-life extending domain
- the antigen-binding domain of the polypeptide of the invention may be short-lived in the bloodstream because of its low molecular weight may be below the permeability threshold of the kidney glomerular membrane. Additionally or alternatively, its pharmacokinetic properties may need to be enhanced. Therefore, the antigen-binding domain of the polypeptide of the invention is coupled either genetically or chemically to a half-life extending domain.
- half-life refers to the time where 50% of an administered polypeptide of the invention are eliminated through biological processes, e.g. metabolism, excretion, etc. Methods for pharmacokinetic analysis and determination of molecule half- life will be familiar to those skilled in the art.
- half-life-extending domain or “half-life extension domain”, as used herein, refers to any moiety which extends the half-life of an antigen-binding domain.
- Such domains are contemplated to include, but are not limited, to plasma proteins, plasma protein binding proteins or peptides, binders to the neonatal Fc receptor (FcRn), and other half-life extension domains known in the art.
- Plasma proteins and plasma protein binding proteins/peptides can be an effective means of improving the pharmacokinetic properties of any molecule.
- albumin which has been extensively investigated for extending the half-life of therapeutic molecules in blood.
- Other plasma proteins are transferrin and immunoglobulin.
- the half-life extending domain may be selected from albumin, or an albumin domain, or an antigen-binding domain that binds specifically to albumin, or an albumin-binding-peptide, or an albumin-binding domain of a Streptococcus protein, or transferrin, or a homo oligomerization domain, or a hetero-oligomerization domain, or a polyethylene glycol moiety.
- Albumin and related moieties Albumin or human serum albumin can be exploited in one of two ways.
- One approach is to directly couple the therapeutic protein to has or to one of its domains.
- a second approach is to use an albumin-binding domain.
- Albumin is the most abundant protein in plasma, present at 50 mg/ml (600 mM), and has a half-life of 19 days in humans. With a molecular mass of about 67 kDa, albumin serves to maintain plasma pH, contributes to colloidal blood pressure, functions as carrier of many metabolites and fatty acids, and serves as a major drug transport protein in plasma. Human albumin is depicted under Accession No. P02768 in the Uniprot database on 30 th March 2020. Albumin is formed by three domains, i.e. albumin domain I spanning aa 19-210, albumin domain II spanning aa 211-403, and albumin domain III spanning aa 404-601.
- the half-life extending domain may comprise the full sequence of HSA shown as SEQ ID NO: 12.
- it may comprise a mutated HSA, such as the ones described in W02010059315.
- the half-life extending domain may comprise one domain of HSA, i.e. domain I of HSA (residues 1-192 of SEQ ID NO: 12), domain II of HSA (residues 193-385 of SEQ ID NO: 12), or domain III of HSA (residues 386-591 of SEQ ID NO: 12).
- the half-life extending domain may comprise a combination of HSA domains, such as domains I and II, I and III, or II and III.
- Noncovalent association with albumin extends the elimination half-time of short-lived proteins.
- the half-life extending domain may comprise the sequence of an antigen-binding domain that binds specifically to albumin.
- anti-HSA antigen-binding domains have been described in the art, such as scFvs, single domain antibodies (NanobodyTM, AlbudAbTM) and Fabs, as well as albumin-binding domains based on antibody mimetics, such as anti-albumin DARPins.
- Anti-serum albumin binding single variable domains have been described, for example, in Holt et al., Protein Eng Des Sel 21:283-8, W004003019, W02008096158, WO05118642, W020060591056, WO201 1/006915, which are incorporated herein by reference.
- the half-life extending domain may comprise the sequence of an albumin-binding-peptide.
- An albumin-binding-peptide includes peptides having the core sequence DICLPRWGCLW (SEQ ID NO: 13), which was generated using peptide phage display to specifically bind to albumin.
- the half-life extending domain may comprise the sequence of an albumin-binding domain of a Streptococcus protein.
- the Streptococcal protein may be Protein G.
- the albuminbinding domain of Streptococcal protein G may be the albumin-binding domain B2A3 (BA) and/or B1A2B2 A3 (BABA).
- polypeptides of the invention comprising a half-life extending domain selected from albumin, or an albumin domain, or an antigen-binding domain that binds specifically to albumin, or an albumin-binding-peptide, or an albumin-binding domain of a Streptococcus protein are depicted in Figure 2A.
- the half-life extending domain may be transferrin.
- Human transferrin is a 698 amino acid protein, of approximately 75kDa (not accounting for glycosylation), with two main domains, N (about 330 amino acids) and C (about 340 amino acids), which appear to originate from a gene duplication. Transferrins are responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation. Human transferrin is depicted under Accession No. P02787 in the Uniprot database on 15 th May 2020.
- the half-life extending domain of the polypeptide of the invention may comprise the amino acid sequence of human transferrin as shown in SEQ ID NO: 14.
- oligomerisation domain refers to a protein sequence, polypeptide or oligopeptide that self-assembles to form an oligomer.
- the oligomer may be a dimer, trimer, tetramer, pentamer, hexamer and so on depending on the number of monomers that assemble together, i.e. two, three, four, five, six and so on, respectively.
- Oligomers can be homo-oligomers, when all the monomers are the same, or heterooligomers, when the monomers are different.
- the oligomer may be a homo-oligomer.
- the oligomerisation domain of the homo-oligomer may be any homo-oligomerisation domain that is suitable for making fusion proteins.
- the oligomerisation domain of the homo-oligomer may be selected from an IgG Fc region or a variant thereof which does not interact with FcyRI, FcyRIIa and FcyRIII, an IgM Fc region, an IgA Fc region, a collagen XVIII trimerizing structural element, a collagen XV trimerizing structural element, a foldon domain, a TenC domain and a homo-oligomerising coiled-coil domain.
- the Fc region is the tail region of an antibody that is formed by the CH2 and the CH3 domains of an antibody.
- Fc regions There are several different Fc regions, according to the antibody isotype and subclass, and these are the Fc regions of an IgGl, an IgG2, an IgG3, an IgG4, an IgM, an IgA, an IgE, and an IgD.
- the Fc regions dimerise, but in the case of IgM and IgA these dimers additionally form pentamers or further dimers, respectively.
- the additional oligomerisation may be particularly advantageous for increasing the valency of the first polypeptide of the invention, or when an avidity effect is to be obtained.
- the Fc region may be the Fc region of an IgGl, an IgG2, an IgG3, an IgG4, an IgM, or an IgA.
- the Fc region may be the Fc region of an IgGl depicted under Uniprot Accession No. P01857 as of 8 th April 2020 or a sequence shown as SEQ ID NO: 61.
- the Fc region may be the Fc region of an IgG2 (SEQ ID NO: 62).
- the Fc region may comprise the hinge region.
- the Fc region may not comprise the hinge region.
- the homo-oligomerisation domain may comprise the sequence shown as SEQ ID NO: 45 or SEQ ID NO: 46, shown below (hinge region is underlined):
- ERKCCVECPPCP APP V AGPS VFLFPPKPKDTLMISRTPEVT C VVVD V SHEDPEV QF NWYVDGVEVHNAKTKPREEQFNSTFRVV S VLT VVHQDWLNGKEYKCKV SNKGL PAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNG QPENNYKTTPPMLD SDGSFFL Y SKLTVDK SRWQQ GNVF S C S VMHE ALHNH YT QK SLSLSPGK
- the present invention also contemplates using a variant of an Fc region of an IgG which does not interact with FcyRI, FcyRIIa and FcyRIII. Mutations that abrogate the effector function of the Fc region have been extensively investigated and are well-known in the art.
- the Fc region of an IgG may contain one or more of the following mutations or mutation combinations:
- Leu234Ala and Leu235Ala LALA
- - Leu234Ala, Leu235Ala LALA
- Pro329Gly PG
- the homo-oligomerisation domain may comprise the Fc region of an IgG which contains the mutations Leu234Ala and Leu235Ala (LALA).
- the homo-oligomerisation domain may comprise the Fc region of an IgG which contains the mutations Leu234Ala, Leu235Ala (LALA) and Pro329Gly (PG).
- HuIgGFc with LALA mutations SEQ ID NO: 47
- HuIgGFc with LALA and PG mutations SEQ ID NO: 48
- the Fc region may comprise the hinge region.
- the Fc region may lack the hinge region.
- the Fc region may be truncated.
- the truncated Fc region may comprise the CH3 domain.
- the truncated Fc region may comprise the hinge region and, optionally, a flexible linker.
- the truncated Fc region may comprise the sequence shown as SEQ ID NO: 99 or SEQ ID NO: 100.
- the present invention also contemplates using a variant of the Fc region of an IgG which does not interact with FcyRI, FcyRIIa and FcyRIII and displays improved circulation or serum half-life.
- One or more of the following mutations or mutation combinations may be combined to the previously described silencing mutations (i.e. mutations that abrogate the effector function of the Fc region) in the IgG Fc region:
- the variant of the Fc region of an IgG which does not interact with FcyRI, FcyRI la and FcyRI 11 and displays improved circulation or serum half-life may comprise mutations Met252Tyr, Ser 254Thr and Thr256Glu (YTE).
- the variant of the Fc region of an IgG which does not interact with FcyRI, FcyRI la and FcyRI 11 and displays improved circulation or serum half-life may comprise the sequence shown as SEQ ID NO: 49.
- HuIgGIFc with LALA, PG and YTE mutations SEQ ID NO: 49
- the homo-oligomerisation domain may be a collagen XVIII trimerizing structural element.
- collagen XVIII trimerizing structural element or “XVIIITSE”, as used herein, refers to the portion of collagen XVIII which is responsible for trimerization between monomers of collagen XVIII.
- the term is also intended to embrace functionally equivalent variants of a XVIIITSE of a naturally occurring collagen XVIII, variants which have been modified in the amino acid sequence without adversely affecting, to any substantial degree, the trimerization properties relative to those of the native collagen XVIII molecule.
- Said modifications include the conservative (or non-conservative) substitution of one or more amino acids for other amino acids, the insertion and/or the deletion of one or more amino acids, provided that the trimerization properties of the native collagen XVIII protein is substantially maintained, i.e., the variant maintains the ability (capacity) of forming trimers with other peptides having the same sequence at physiological conditions.
- the XVIIITSE may be a polypeptide having the amino acid sequence shown in SEQ ID NO: 101
- the oligomerisation domain may be a collagen XV trimerizing structural element.
- collagen XV trimerizing structural element or “XVTSE”, as used herein, refers to the portion of collagen XV which is responsible for trimerization between monomers of collagen XV.
- XVTSE collagen XV trimerizing structural element
- the term is also intended to embrace functionally equivalent variants of a XVTSE of a naturally occurring collagen XV, variants which have been modified in the amino acid sequence without adversely affecting, to any substantial degree, the trimerization properties relative to those of the native collagen XV molecule.
- Said modifications include, the conservative (or non-conservative) substitution of one or more amino acids for other amino acids, the insertion and/or the deletion of one or more amino acids, provided that the trimerization properties of the native collagen XV protein is substantially maintained, i.e., the variant maintains the ability (capacity) of forming trimers with other peptides having the same sequence at physiological conditions.
- the XVTSE may be a polypeptide having the amino acid sequence shown in SEQ ID NO: 102
- the oligomerisation domain may be a foldon domain.
- foldon domain refers to the C-terminal amino acid residues of the trimeric protein fibritin from bacteriophage T4 (SEQ ID NO: 103).
- the foldon domain promotes folding and trimerisation of fibritin. This feature has been exploited to trimerise other molecules.
- the oligomerisation domain may be a TenC domain.
- the term “TenC domain”, as used herein, refers to the oligomerisation domain located at the N-terminus of Tenascin C (TN- C).
- the TenC domain may be human (SEQ ID NO: 104) or from chicken (SEQ ID NO: 105).
- the TenC domain forms trimers.
- the oligomerisation domain may be a coiled coil domain.
- a “coiled coil” is a structural motif in which two to seven alpha helices are wrapped together like the strands of a rope. Many endogenous proteins incorporate coiled coil domains.
- the coiled coil domain may be involved in protein folding (e.g. it interacts with several alpha helical motifs within the same protein chain) or responsible for protein-protein interaction. In the latter case, the coiled coil can initiate homo or hetero oligomer structures.
- Coiled coils usually contain a repeated pattern, hxxhcxc, of hydrophobic (h) and charged (c) amino-acid residues, referred to as a heptad repeat.
- the positions in the heptad repeat are usually labelled abcdefg, where a and d are the hydrophobic positions, often being occupied by isoleucine, leucine, or valine.
- proteins which contain a homo-oligomerising coiled coil domain include, but are not limited to, cartilage-oligomeric matrix protein (COMP), kinesin motor protein, hepatitis D delta antigen, archaeal box C/D sRNP core protein, mannose-binding protein A, coiled-coil serine-rich protein 1, polypeptide release factor 2, SNAP-25, SNARE, Lac repressor or apolipoprotein E.
- cartilage-oligomeric matrix protein kinesin motor protein
- hepatitis D delta antigen hepatitis D delta antigen
- archaeal box C/D sRNP core protein mannose-binding protein A
- coiled-coil serine-rich protein 1 polypeptide release factor 2
- SNAP-25 SNARE
- Lac repressor or apolipoprotein E.
- Cartilage oligomeric matrix protein (COMP) homopentamer (SEQ ID NO: 106)
- Kinesin motor protein parallel homodimer (SEQ ID NO: 107)
- Hepatitis D delta antigen parallel homodimer (SEQ ID NO: 108) GREDILEQWVSGRKKLEELERDLRKLKKKIKKLEEDNPWLGNIKGIIGKY
- Archaeal box C/D sRNP core protein anti-parallel heterodimer (SEQ ID NO: 109)
- Mannose-binding protein A parallel homotrimer (SEQ ID NO: 110)
- Coiled-coil serine-rich protein 1 parallel homotrimer (SEQ ID NO: 111)
- the oligomerisation domain may be a p53 oligomerisation domain.
- the p53 domain may comprise the sequence shown as SEQ ID NO: 112.
- the p53 domain forms tetramers.
- p53 oligomerisation domain (SEQ ID NO: 112) KKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG
- the half-life extending domain may be a hetero-oligomerisation domain.
- the use of heterooligomerisation domains may be advantageous when it is intended that the polypeptide of the invention contains two or more different antigen-binding domains.
- a hetero-oligomerisation domain such as a heterodimerization domain
- hetero-oligomerisation domains may be used in the context of the present invention.
- Non-limiting examples of hetero-oligomerisation domains are described in Brinkmann & Kontermann (2017, MAbs 9:182-212), and include the dock-and-lock (DNL) modules, knobs-into-holes modified CH3 domains, SEEDbodies, bispecific tetravalent Fc or IgG fusions, dual variable domain Ig (DVD), the barnase-barstar domains, and hetero- oligomerising coiled coil domains.
- DNL dock-and-lock
- the basis of the DNL method is the exploitation of the specific protein-protein interactions occurring in nature between the regulatory (R) subunits of protein kinase (PKA) and the anchoring domain (AD) of A-kinase anchoring proteins (AKAPs).
- R regulatory
- AD anchoring domain
- AKAPs A-kinase anchoring proteins
- the dimerization domain and AKAP binding domain of human Rlla are both located within the same amino-terminal 44-amino acid sequence, which is termed the dimerization and docking domain (DDD)
- DDD dimerization and docking domain
- a recombinant protein is constructed by linking a DDD sequence to the compound of interest, for example the ectodomain of hACE2. Because the DDD sequence effects the spontaneous formation of a dimer, the resulting recombinant protein is a divalent compound, for example a divalent ectodomain of hACE2.
- a second recombinant protein is prepared by fusing an AD sequence. This second recombinant protein may comprise domain C, domain ABD, or domain ALB, which will be described in more detail in following sections of present invention.
- the dimeric motif of DDD in the first recombinant protein creates a docking site for binding to the AD sequence, thus facilitating a ready association of the dimeric ectodomain of hACE2 construct with the monomeric domain C, domain ABD, or domain ALB to form a binary, trimeric complex.
- This binding event is made irreversible with a subsequent reaction to secure the 2 entities covalently via disulfide bridges between the inserted cysteine residues.
- This reaction occurs very efficiently, because the initial binding interactions bring the reactive thiol groups on both the DDD and AD into proximity to ligate site-specifically.
- site-specific ligations preserve the original activities of the 2 precursors.
- the DNL method was disclosed in US provisional application 60/751196, which is incorporated herein by reference in its entirety.
- “Knobs-into-holes” is a design strategy for engineering antibody heavy chain homodimers for heterodimerization.
- a 'knob' variant was first obtained by replacement of a small amino acid with a larger one in the CH3 domain of an IgG: T366Y.
- the knob was designed to insert into a 'hole' in the CH3 domain of a different IgG created by judicious replacement of a large residue with a smaller one: Y407T.
- knobs-into- holes structure comprises mutations S354C, T366W in the CH3 domain of one IgG chain, and Y349C, T366S, L368A, and Y407V in the CH3 domain of other IgG chain.
- Other paired variant combinations have been developed.
- Knobs-into-holes fusion proteins consist of [IgGl hinge]-CH2-[Knobs-into-holes CH3], that may be genetically linked to one or more fusion partners. This results in bispecific molecules, such as the general bispecific scFv-based fusion proteins depicted in Figure 2B.
- SEED strand-exchange engineered domain
- Another immunoglobulin-based architecture that may be used in the context of the present invention consists in fusing antigen binding domains (e.g. scFv or dAb) of different specificity to the constant domain of human k chain (CL) and the first constant domain of human heavy chain (CHI) to form two polypeptides, (ABDl)-CL and (ABD2)-CH1-CH2- CH3, respectively.
- antigen binding domains e.g. scFv or dAb
- CL constant domain of human k chain
- CHI human heavy chain
- These molecules are termed bispecific tetravalent Fc fusions.
- the two polypeptides are co-expressed in cells. Association between the heavy and the light chains forms a covalently linked hetero-tetramer with dual specificity.
- This approach yields a homogeneous bispecific IgG-like antibody product with each molecule containing four antigen binding sites, two for each of its target antigen.
- the BsAb retains not
- Sequence examples include human IgGl CHI (SEQ ID NO: 43, human IgGl constant kappa (SEQ ID NO: 44), hinge-IgGl Fc region (SEQ ID NO: 45), and hinge-IgG2 Fc region (SEQ ID NO: 46).
- antigen-binding domain(s) according to the invention CL or CHl-hinge-CH2-CH3 chains may be combined in different arrangements.
- antigen-binding domains of different specificity may each be fused to one of the CL or CHl-hinge-CH2-CH3 chains, or to only one of the CL or CHl-hinge-CH2-CH3 chains while the other may be left “empty” (i.e. not fused to an antigen binding domain).
- Variants of the Fc region of an IgG which do not interact with FcyRI, FcyRIIa and FcyRIII and/or which display improved circulation or serum half-life, which have been described in detail in the context of the homo-oligomerisation domain, are equally applicable to the immunoglobulin-based architectures of the hetero-oligomerisation domain.
- the barnase-barstar system is a multimerisation module based on the tight interaction between barnase and barstar.
- Bamase is a 110 aa secreted ribonuclease from Bacillus amyloliquefaciens .
- Barstar is an 89 aa cytoplasmic barnase inhibitor with which the host protects itself. They rapidly form a complex with a KD of ⁇ 10 '14 M. Both the N- and C- termini of both proteins are accessible and available for fusions (Deyev et al., 2003, Nat Biotech 21:1486-92).
- the hetero-oligomerisation domain may be a coiled coil domain.
- a “coiled coil” is a structural motif in which two to seven alpha helices are wrapped together like the strands of a rope. Many endogenous proteins incorporate coiled coil domains.
- the coiled coil domain may be involved in protein folding (e.g. it interacts with several alpha helical motifs within the same protein chain) or responsible for protein-protein interaction. In the latter case, the coiled coil can initiate homo or hetero oligomer structures.
- the structure of coiled coil domains is well known in the art. For example, as described by Lupas & Gruber (2007, Advances in Protein Chemistry 70:37-8).
- Coiled coils usually contain a repeated pattern, hxxhcxc, of hydrophobic (h) and charged (c) amino-acid residues, referred to as a heptad repeat.
- the positions in the heptad repeat are usually labelled abcdefg, where a and d are the hydrophobic positions, often being occupied by isoleucine, leucine, or valine.
- proteins which contain a hetero-oligomerising coiled coil domain include, but are not limited to, polypeptide release factor 2, SNAP-25, SNARE, Lac repressor and apolipoprotein E.
- heterooligomerising coiled coil domains include
- Polypeptide release factor 2 anti-parallel heterotrimer
- VVDTLDQMKQ GLED V S GLLEL A VE ADDEETFNE A V AELD ALEEKL AQLEFR (SEQ ID NO: 16)
- Apolipoprotein E anti-parallel heterotetramer SGQRWEL ALGRF WD YLRW VQTL SEQ V QEELL S S Q VT QELRALMDETMKELK A Y KSELEEQLTARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRV RLASHLRKLRKRLLRD ADDLQKRLAVY Q A (SEQ ID No. 21)
- a hetero-oligomerisation domain provides a possibility for multiple structures of the polypeptide of the invention, since the one or more antigen-binding domains may be fused to only one or all of the different hetero-oligomerisation domains.
- the polypeptide of the invention comprises two antigen binding domains and a heterodimerisation domain (e.g. knob-into-holes domains)
- the two antigen binding domains may be fused in tandem to only one of the heterodimerisation domains, or only one antigen-binding domain fused to each of the heterodimerisation domains ( Figure 2B). This is advantageous in embodiments where exact conformations are required for binding to various epitopes on a single hACE2 molecule while preventing cross-linking with other hACE2 molecules.
- the ability of the polypeptide of the invention to form dimers, trimers or higher heterooligomers can be determined by conventional methods known by the skilled person in the art.
- the ability of a polypeptide of the invention comprising a trimerising domain, such as the DNL system, to form a trimer can be determined by using standard chromatographic techniques.
- the variant to be assessed is put under suitable trimerisation conditions and the complex is subjected to a standard chromatographic assay under non denaturing conditions so that the eventually formed complex (trimer) is not altered. If the variant trimerises properly, the molecular size of the complex would be three times heavier than the molecular size of a single molecule of the variant.
- the molecular size of the complex can be revealed by using standard methods such as analytical centrifugation, mass spectrometry, size-exclusion chromatography, sedimentation velocity, etc.
- the first polypeptide of the invention may be conjugated to polyethylene glycol (PEG), or pegylated.
- PEG polyethylene glycol
- the antigen-binding domain and the half-life extending domain may be joined by a linker.
- the linker provides spatial separation between antigen-binding domain and the half-life extending domain.
- the linker may be a flexible linker. This type of linkers allows for torsion of the antigen-binding domain respective of the half-life extending domain, which may be beneficial when the antigen-binding domain interacts with hACE2.
- Non-limiting examples of flexible linkers that may be used in the polypeptide of the invention include:
- the linker may be the (Gly 4 Ser)3 linker (SEQ ID NO: 23).
- the movement of the antigen-binding domain respective of the half-life extending domain is constrained. This may be achieved using a short linker or an inflexible linker.
- short linkers that may be used in the first polypeptide of the invention include:
- the linker may be inflexible or rigid.
- Inflexible linkers that may be used in the first polypeptide of the invention include those forming part of the families of linkers (EAAAK)n (SEQ ID NO: 114), (EP) n , (KP) n , and (TRP) n .
- Non-limiting examples of inflexible or rigid linkers include: - LEAEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAA KALE (SEQ ID NO: 37),
- polypeptide of the invention comprises two or more antigen-binding domains to ensure that binding occurs on the same hACE2 molecule, and thus prevent cross-linking of hACE2.
- polypeptide of the invention comprises two or more antigen-binding domains in tandem, these may be joined by a linker as described herein.
- the different components of the polypeptide of the invention i.e. the antigen-binding domain and the half-life extending domain and, optionally, the at least one additional antigen binding domain, may take any orientation.
- the half-life extending domain comprises a domain which forms monomers, i.e. albumin, an albumin domain, an antigen-binding domain that binds specifically to albumin, an albumin-binding-peptide, an albumin-binding domain of a Streptococcus protein, or transferrin
- the polypeptide of the invention may have one of the following domain orientations:
- ABD is the antibody-binding domain that binds specifically to the hACE2 ectodomain
- HLED is the half-life extending domain
- ABDx is an additional antibody-binding domain that binds specifically to the hACE2 ectodomain
- ABDy is an additional antibody-binding domain that binds specifically to the hACE2 ectodomain
- ABD, ABDx and, where present, ABDy recognise different epitopes on the hACE2 ectodomain.
- the half-life extending domain comprises a domain which forms hetero-oligomers, i.e. hetero-oligomerisation domains.
- the polypeptide of the present invention may comprise a signal peptide at its N-terminus so that when the polypeptide is expressed inside a cell, the nascent protein is directed to the endoplasmic reticulum and subsequently secreted.
- the core of the signal peptide or leader sequence may contain a long stretch of hydrophobic amino acids that has a tendency to form a single alpha-helix.
- the signal peptide may begin with a short positively charged stretch of amino acids, which helps to enforce proper topology of the polypeptide during translocation.
- At the end of the signal peptide there is typically a stretch of amino acids that is recognised and cleaved by signal peptidase.
- Signal peptidase may cleave either during or after completion of translocation to generate a free signal peptide and a mature protein.
- the free signal peptides are then digested by specific proteases.
- the signal peptide may be at the amino terminus of the molecule.
- the signal peptide may comprise the SEQ ID NO: 30-34 or a variant thereof having 5, 4, 3, 2 or 1 amino acid mutations (insertions, substitutions or additions) provided that the signal peptide still functions to cause cell surface expression of the protein.
- SEQ ID NO: 30 MGTSLLCWMALCLLGADHADG
- the signal peptide of SEQ ID NO: 30 is compact and highly efficient. It is predicted to give about 95% cleavage after the terminal glycine, giving efficient removal by signal peptidase.
- SEQ ID NO: 31 MSLP VT ALLLPLALLLHAARP
- the signal peptide of SEQ ID NO: 31 is derived from IgGl.
- SEQ ID NO: 32 MA VPT Q VLGLLLLWLTD ARC
- the signal peptide of SEQ ID NO: 32 is derived from CD8.
- the signal peptide of SEQ ID NO: 33 is derived from mouse Ig Kappa.
- SEQ ID NO: 34 MGW S CIILFL V AT AT GVHS
- the signal peptide of SEQ ID NO: 34 is derived from human IgG2 heavy chain.
- the present invention also provides a nucleic acid encoding the polypeptide of the invention, hereinafter “the nucleic acid of the invention”.
- the nucleic acid construct encoding such a polynucleotide may have one of the following structure: ABD-linker 1 -HDEL 1 -coexpr-ABDx-linker2-HDEL2 or
- HDEL 1 -linker 1 -ABD-coexpr-HDEL2-linker2-ABDx in which:
- ABD is a nucleic acid encoding the antibody-binding domain that binds specifically to the hACE2 ectodomain
- - HLED1 is a nucleic acid encoding one hetero-oligomerisation domain
- - HLED2 is a nucleic acid encoding the other hetero-oligomerisation domain
- ABDx is a nucleic acid encoding an additional antibody-binding domain that binds specifically to the hACE2 ectodomain
- linker is a nucleic acid encoding a linker
- coexpr is a nucleic acid encoding a sequence enabling co-expression of the first and second polypeptides
- ABD and ABDx recognise different epitopes on the hACE2 ectodomain.
- nucleic acid sequences encoding the two or more polypeptides may be in either order in the construct. Additionally, for structures mentioned above, nucleic acid sequences encoding each of the different domains may be in any orientation.
- nucleic acid structures are not intended to be exhaustive but merely an indication for the skilled person. Different construct structures may be needed to encode different polypeptide structures as described previously in the context of the first aspect of the invention.
- the different monomers may be encoded by separate nucleic acids.
- polypeptide of the invention has been described in detail in the context of the first aspect of the invention and its definitions, features and embodiments apply equally to this aspect of the invention.
- polynucleotide “nucleotide”, and “nucleic acid” are intended to be synonymous with each other.
- nucleic acid sequences and constructs of the invention may contain alternative codons in regions of sequence encoding the same or similar amino acid sequences, in order to avoid homologous recombination.
- Nucleic acids according to the invention may comprise DNA or RNA. They may be single- stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the use as described herein, it is to be understood that the polynucleotides may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of interest.
- variant in relation to a nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence.
- “coexpr” is a nucleic acid sequence enabling co-expression of two polypeptides as separate entities. It may be a sequence encoding a cleavage site, such that the nucleic acid construct produces both polypeptides, joined by a cleavage site(s). The cleavage site may be self-cleaving, such that when the polypeptide is produced, it is immediately cleaved into individual peptides without the need for any external cleavage activity.
- the cleavage site may be any sequence which enables the two polypeptides to become separated.
- cleavage is used herein for convenience, but the cleavage site may cause the peptides to separate into individual entities by a mechanism other than classical cleavage.
- FMDV Foot-and-Mouth disease virus
- various models have been proposed for to account for the “cleavage” activity: proteolysis by a host-cell proteinase, autoproteolysis or a translational effect (Donnelly et al., 2001, J Gen Virol 82:1027-41).
- the exact mechanism of such “cleavage” is not important for the purposes of the present invention, as long as the cleavage site, when positioned between nucleic acid sequences which encode proteins, causes the proteins to be expressed as separate entities.
- the cleavage site may, for example be a furin cleavage site, a Tobacco Etch Virus (TEV) cleavage site or encode a self-cleaving peptide.
- TSV Tobacco Etch Virus
- a ‘self-cleaving peptide’ refers to a peptide which functions such that when the polypeptide comprising the proteins and the self-cleaving peptide is produced, it is immediately “cleaved” or separated into distinct and discrete first and second polypeptides without the need for any external cleavage activity.
- the self-cleaving peptide may be a 2A self-cleaving peptide from an aphtho- or a cardiovirus.
- the primary 2A/2B cleavage of the aptho- and cardioviruses is mediated by 2A “cleaving” at its own C-terminus.
- apthoviruses such as foot-and-mouth disease viruses (FMDV) and equine rhinitis A virus
- the 2A region is a short section of about 18 amino acids, which, together with the N-terminal residue of protein 2B (a conserved proline residue) represents an autonomous element capable of mediating “cleavage” at its own C- terminus (Donelly et al (2001) as above).
- 2A-like sequences have been found in picomaviruses other than aptho- or cardioviruses, ‘picornavirus-like’ insect viruses, type C rotaviruses and repeated sequences within Trypanosoma spp and a bacterial sequence (Donnelly et al (2001) as above).
- the cleavage site may comprise the 2A-like sequence shown as SEQ ID NO: 113 (RAEGRGSLLTCGDVEENPGP).
- the nucleic acid of the invention can contain a regulatory sequence operatively linked for the expression of the nucleotide sequence encoding the first polypeptide of the invention, thereby forming a gene construct, hereinafter the “gene construct of the invention”.
- the term “operatively linked” means that the antibody encoded by the nucleic acid sequence of the invention is expressed in the correct reading frame under control of the expression control or regulating sequences. Therefore, in another aspect, the invention provides an expression cassette, hereinafter “the expression cassette of the invention”, comprising the gene construct of the invention operatively linked to an expression control sequence.
- the gene construct of the invention can be obtained through the use of techniques that are widely known in the art.
- the expression cassette may comprise one or more control sequences.
- Control sequences are sequences that control and regulate transcription and, where appropriate, the translation of said antibody, and include promoter sequences, transcriptional regulators encoding sequences, ribosome binding sequences (RBS) and/or transcription terminating sequences.
- the expression cassette of the present invention may additionally include an enhancer, which may be adjacent to or distant from the promoter sequence and can function to increase transcription from the same.
- the expression control sequence may functional in prokaryotic cells or in eukaryotic cells and organisms, such as mammalian cells.
- the expression cassette may comprise a promoter. Any promoter may be used in this methodology.
- nucleic acids are required to encode the polypeptide of the invention where the half-life extending domain comprises a hetero-oligomerisation domain.
- the skilled person will readily know how to make the necessary modifications to obtain the different nucleic acids encoding for these heterooligomeric first, second or third polypeptides of the invention. 5.
- the present invention also provides a vector, or kit of vectors, which comprises a nucleic acid of the invention, or an expression cassette of the invention.
- a vector may be used to introduce the nucleic acid or expression cassette into a host cell so that it expresses the polypeptide of the invention.
- polypeptide of the invention “nucleic acid of the invention” and “expression cassette or the invention” have been described in detail in the context of previous aspects of the invention and their features and embodiments apply equally to this aspect of the invention.
- the vector may, for example, be a plasmid or a viral vector, such as a retroviral vector or a lentiviral vector, or a transposon-based vector or synthetic mRNA.
- Another aspect of the present invention relates to a cell, hereinafter “the cell of the invention”, comprising the nucleic acid of the invention, the nucleic acid of the invention, the expression cassette of the invention, the vector of the invention, or the vector of the invention.
- the cell may comprise a nucleic acid, or an expression cassette, or a vector according to the present invention, and may express the polypeptide of the invention.
- polypeptide of the invention “nucleic acid of the invention”, “expression cassette or the invention”, and “vector of the invention” have been described in detail in the context of previous aspects of the invention and their features and embodiments apply equally to this aspect of the invention.
- the cell may be prokaryotic or eukaryotic.
- Cells suitable for performing the invention include, without limitation, mammalian, plant, insect, fungal and bacterial cells.
- Mammalian cells suitable for the present invention include epithelial cell lines, osteosarcoma cell lines, neuroblastoma cell lines, epithelial carcinomas, glial cells, hepatic cell lines, CHO (Chinese Hamster Ovary) cells, COS, BHK cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, 293 and 293T cells, PER.C6 cells, NTERA-2 human ECCs cells, D3 cells of the mESCs line, human embryonic stem cells such as HS293, hMSCs and BGVOl, SHEF1, SHEF2 and HS181, NIH3T3 cells, REH and MCF-7 cells.
- Bacterial cells include, without limitation, cells from Gram positive bacteria such as species of the genus Bacillus , Streptomyces and Staphylococcus and Gram-negative bacterial cells such as cells of the genus Escherichia and Pseudomonas.
- Fungal cells preferably include yeast cells such as Saccharomyces, Pichia pastoris and Hansenula polymorpha.
- Insect cells include, without limitation, Drosophila cells and Sf9 cells.
- Plant cells include, among others, cells of crop plants such as cereals, medicinal, ornamental or bulbs.
- the polypeptide of the invention may be produced by culturing the host cells for a period of time sufficient to allow for expression of the polypeptide in the host cells or, more preferably, secretion of the polypeptide into the culture medium in which the host cells are grown.
- the polypeptide of the invention can be recovered from the culture medium using standard protein purification methods. For example, where the half-life extending domain is albumin or an albumin domain the purification can be advantageously carried out by affinity chromatography using albumin-binding resins and columns.
- the present invention also relates to a pharmaceutical composition containing the polypeptide of the invention, hereinafter “the pharmaceutical composition of the invention”.
- the pharmaceutical composition may additionally comprise a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.
- the pharmaceutical composition may optionally comprise one or more further pharmaceutically active polypeptides and/or compounds.
- Such a formulation may, for example, be in a form suitable for intravenous infusion.
- polypeptide of the invention has been described in detail in the context of previous aspects of the invention and its definitions and particular features apply equally to this aspect of the invention.
- pharmaceutically acceptable carrier means any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- Some examples of pharmaceutically acceptable carriers are water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- additional examples of pharmaceutically acceptable substances are wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the polypeptide of the invention.
- compositions may be in a variety of forms, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g. injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, and liposomes.
- liquid solutions e.g. injectable and infusible solutions
- dispersions or suspensions tablets, pills, powders, and liposomes.
- the preferred form depends on the intended mode of administration and therapeutic application.
- the administration of the polypeptide of the invention can be accomplished using any of a variety of routes that make the active ingredient bioavailable.
- the agent can be administered via an oral, mucosal, buccal, intranasal, inhalable, intravenous, subcutaneous, transcutaneous, intramuscular, intraperitoneal, parenteral or topical route.
- Oral administration may be by inhalation, by nebulisation or nasally.
- the polypeptide of the invention may be administered locally, for example by catheter or stent, or systemically.
- compositions comprising the polypeptide of the invention may be administered to the subject in a variety of pharmaceutically acceptable dosing forms, which will be familiar to those skilled in the art.
- the polypeptide of the invention may be administered via the nasal route using a nasal insufflator device. Examples of these are already employed for commercial powder systems intended for nasal application (e.g. Fisons Lomudal System). Details of other devices are well-known in the art.
- Other delivery routes for the polypeptide of the invention include via the pulmonary route using a powder inhaler or metered dose inhaler, via the buccal route formulated into a tablet or a buccal patch, and via the oral route in the form of a tablet, a capsule or a pellet (which compositions may administer agent via the stomach, the small intestine or the colon), all of which may be formulated in accordance with techniques which are well known to those skilled in the art.
- a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.
- coronavirus S protein of the polypeptides of the invention makes these molecules capable of neutralising coronavirus virions and prevent cell infection. This can be exploited for therapeutic purposes.
- the present invention provides a polypeptide of the invention for use in medicine.
- the invention provides a method for neutralising a coronavirus by administering a polypeptide of the invention to a patient in need thereof.
- the coronavirus may be a coronavirus that uses ACE2 as a receptor to infect cells.
- the coronavirus may be SARS- CoV-2 or SARS-CoV.
- the SARS-CoV-2 strain may be selected from wild-type, variant D614G, variant A222V, variant S477N, variant B.l.1.7, variant B.1.351, variant B.1.1.28, variant P.1, variant P.2, variant B.1.526, variants B.1.526.1, variant B.1.617, variant B.1.617.1, variant B.1.617.2, variant B.1.617.2, and variant B.1.617.3.
- the present invention provides a method for treating a coronavirus infection or a condition or disorder resulting from this infection in a subject, hereinafter “the method of treatment of the invention”, which comprises the step of administering a polypeptide of the invention to a subject in need thereof.
- the administration step may be in the form of a pharmaceutical composition as described above.
- This aspect of the invention may be alternatively formulated as a polypeptide of the invention for use in the treatment a coronavirus infection or a condition or disorder resulting from this infection.
- This aspect of the invention may be alternatively formulated as the use of a polypeptide of the invention in the manufacture of a medicament for treating a coronavirus infection or a condition or disorder resulting from this infection.
- polypeptide of the invention and “pharmaceutical composition of the invention” have been described in detail in the context of previous aspects of the invention and its definitions and particular features apply equally to this aspect of the invention.
- a method for treating a coronavirus infection or a condition or disorder resulting from this infection relates to the therapeutic use of the polypeptide of the invention, which may be administered to a subject who has been infected with a coronavirus, or is suspected to have been infected with a coronavirus, or has tested positive for a coronavirus in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease.
- the method for preventing a coronavirus infection or a condition or disorder resulting from this infection relates to the prophylactic use of the polypeptide of the invention.
- such polypeptide may be administered to a subject who has not yet contracted the coronavirus infection or condition or disorder resulting from this infection and/or who is not showing any symptoms of the coronavirus infection or condition or disorder resulting from this infection to prevent or impair the coronavirus from infecting the cells of the subject or to reduce or prevent development of at least one symptom associated with the coronavirus infection or condition or disorder resulting from this infection.
- the subject may have a predisposition for or be thought to be at risk of contracting a coronavirus infection or a condition or disorder resulting from this infection.
- the present invention provides a method for treating a subject having COVID-19 of unknown SARS-CoV-2 strain, comprising a step of administering the polypeptide of the invention or a pharmaceutical composition of the invention to the subject.
- This aspect may be alternatively formulated as a polypeptide of the invention or a pharmaceutical composition of the invention for use in the treatment of COVID-19 of unknown SARS-CoV-2 strain.
- This aspect may be alternatively formulated as the use of a polypeptide of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for treating COVID-19 of unknown SARS-CoV-2 strain.
- the present invention provides a method for treating a subject previously immunised with a vaccine based on S protein depicted under Uniprot accession number P0DTC2, comprising a step of administering a polypeptide of the invention or a pharmaceutical composition of the invention to the subject.
- This aspect may be alternatively formulated as a polypeptide of the invention or a pharmaceutical composition of the invention for use in the treatment of a subject previously immunised with a vaccine based on S protein depicted under Uniprot accession number P0DTC2.
- This aspect may be alternatively formulated as the use of a polypeptide of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for treating a subject previously immunised with a vaccine based on S protein depicted under Uniprot accession number P0DTC2.
- the present invention provides a method for treating a subject previously treated with antibodies specific to S protein depicted under Uniprot accession number P0DTC2, comprising a step of administering a polypeptide of the invention or a pharmaceutical composition of the invention to the subject.
- This aspect may be alternatively formulated as a polypeptide of the invention or a pharmaceutical composition of the invention for use in the treatment of a subject previously treated with antibodies specific to S protein depicted under Uniprot accession number P0DTC2.
- This aspect may be alternatively formulated as the use of a polypeptide of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for treating a subject previously treated with antibodies specific to S protein depicted under Uniprot accession number P0DTC2.
- the present invention provides a method for treating a subject previously infected with a first SARS-CoV-2 strain who is currently infected with a second SARS- CoV-2 strain, wherein the first and second SARS-CoV-2 strains are different, comprising a step of administering a polypeptide of the invention or a pharmaceutical composition of the invention to the subject.
- This aspect may be alternatively formulated as a polypeptide of the invention or a pharmaceutical composition of the invention for use in the treatment of a subject previously infected with a first SARS-CoV-2 strain who is currently infected with a second SARS-CoV-2 strain, wherein the first and second SARS-CoV-2 strains are different.
- This aspect may be alternatively formulated as the use of a polypeptide of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for treating a subject previously infected with a first SARS-CoV-2 strain who is currently infected with a second SARS-CoV-2 strain, wherein the first and second SARS-CoV-2 strains are different.
- the first and second SARS-CoV-2 strains may be selected from wild-type, variant D614G, variant A222V, variant S477N, variant B.l.1.7, variant B.1.351, variant B.1.1.28, variant P.1, variant P.2, variant B.1.526, variants B.1.526.1, variant B.1.617, variant B.1.617.1, variant B.1.617.2, variant B.1.617.2, and variant B.1.617.3. It will be appreciated that these aspects are not limited to the SARS-CoV-2 strains described above since the present invention is useful in the treatment of any other SARS-CoV-2 variants existent at the time of filing or of any future variants that may emerge.
- polypeptide of the invention or the pharmaceutical composition of the invention may be used therapeutically in the treatment and/or prevention of a coronavirus infection or a condition or disorder resulting from this infection caused by a different coronavirus that uses ACE2 as a receptor to infect cells.
- the present invention provides a method for treating a coronavirus infection of one SARS-CoV-2 strain selected from wild-type, variant D614G, variant A222V, variant S477N, variant B.l.1.7, variant B.1.351, variant B.1.1.28, variant P.1, variant P.2, variant B.1.526, variants B.1.526.1, variant B.1.617, variant B.1.617.1, variant B.1.617.2, variant B.1.617.2, and variant B.1.617.3, comprising a step of administering a polypeptide of the invention or a pharmaceutical composition of the invention to the subject.
- This aspect may be alternatively formulated as a polypeptide of the invention or a pharmaceutical composition of the invention for use in the treatment of a coronavirus infection of one SARS-CoV-2 strain selected from wild-type, variant D614G, variant A222V, variant S477N, variant B.l.1.7, variant B.1.351, and variant B.1.1.28.
- This aspect may be alternatively formulated as the use of a polypeptide of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for treating a coronavirus infection of one SARS-CoV-2 strain selected from wild-type, variant D614G, variant A222V, variant S477N, variant B.l.1.7, variant B.1.351, variant B.1.1.28, variant P.1, variant P.2, variant B.1.526, variants B.1.526.1, variant B.1.617, variant B.1.617.1, variant B.1.617.2, variant B.1.617.2, and variant B.1.617.3.
- this aspect is not limited to the SARS-CoV-2 strains described above since the present invention is useful in the treatment of any other SARS-CoV-2 variants existent at the time of filing or of any future variants that may emerge. It will also be immediately understood that these aspects are not limited to SARS-CoV-2 and that the polypeptide of the invention or the pharmaceutical composition of the invention may be used therapeutically in the treatment and/or prevention of a coronavirus infection or a condition or disorder resulting from this infection caused by a different coronavirus that uses ACE2 as a receptor to infect cells.
- These therapeutic applications will comprise the administration of a therapeutically effective amount of the polypeptide of the invention.
- polypeptide of the invention and “pharmaceutical composition of the invention” have been described in detail in the context of previous aspects of the invention and their definitions and particular features apply equally to these aspects of the invention.
- the treatment of a coronavirus disease in a subject may comprise the step of administrating the polypeptide of the invention to the subject, to cause complete or partial neutralisation of the coronaviruses.
- the present invention provides a method of neutralising a coronavirus infection, comprising a step of contacting a polypeptide of the invention with a cell infected with said coronavirus.
- the polypeptide of the invention may be in the form of a pharmaceutical composition as described above.
- polypeptide of the invention and “pharmaceutical composition of the invention” have been described in detail in the context of previous aspects of the invention and their definitions and particular features apply equally to this aspect of the invention.
- subject or “individual”, as used in the context of the present invention, refers to members of mammalian species.
- the subject may be a human patient of any gender, age or race.
- the subject may be a non-human mammal infected with coronavirus.
- the polypeptide of the invention or the pharmaceutical composition of the invention may be administered to a non-human mammal infected with coronavirus for veterinary purposes or as an animal model of human disease.
- animal models may be useful for evaluating the therapeutic efficacy of the polypeptides of this invention.
- Non-limiting examples of nonhuman mammal that may be subject to treatment according to the invention include a cat or any other feline, a dog or any other canid, a mouse, a rat or any other rodent, a pig, a primate, a camelid, and a bat.
- terapéuticaally effective amount refers to the amount of the polypeptide of the invention which is required to achieve an appreciable prevention, neutralisation, cure, delay, reduction of the severity of, or amelioration of one or more symptoms of a coronavirus disease.
- a coronavirus infection or a condition or disorder resulting from this infection refers to an infection, condition or disorder caused by a coronavirus.
- the coronaviruses can cause varieties of diseases in humans and other animals, including respiratory, enteric, renal, and neurological diseases. Particularly important are the diseases caused by SARS-CoV and SARS-CoV-2 coronaviruses because of the severe acute respiratory syndrome that they cause.
- the coronavirus condition or disorder may be coronavirus disease 2019 (COVID-19).
- the disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019-20 coronavirus pandemic.
- Common symptoms include fever, cough and shortness of breath.
- Other symptoms may include fatigue, muscle pain, diarrhoea, nausea, sore throat, loss of smell and abdominal pain. While the majority of cases result in mild symptoms, some progress to viral pneumonia and multi-organ failure.
- COVID-19 manifests as a clotting disorder, which may cause pulmonary embolism and hypoxia. Pulmonary vasculature affected by pulmonary embolism is not fully restored and can cause permanent fibrosis of the lining of blood vessels. Pulmonary fibrosis may also be the result of prolonged mechanical ventilation; even prolonged use of high concentration oxygen can lead to lung injury and result in fibrosis. Permanent fibrosis may lead to chronic thromboembolic pulmonary hypertension (CTEPH). Additionally, the clotting disorder causes end organ damage, primarily kidney. Kidney injury does not fully recover and may lead to chronic kidney disease (CKD) in post- COVID19 patients.
- CKD chronic kidney disease
- Severe COVID-19 presents with a cytokine storm or cytokine release syndrome (CRS), which is an immediate and intense response of the immune system to viral infection.
- CRS cytokine storm or cytokine release syndrome
- Kawasaki disease is an autoimmune disease in which blood vessels throughout the body become inflamed. It is considered a “post-viral” autoimmune disease.
- Guillain-Barre syndrome is a neurological disorder where the immune system responds to an infection and ends up mistakenly attacking nerve cells, resulting in muscle weakness and eventually paralysis. Thus, severe COVID-19 may also cause an incidence of other more prevalent autoimmune diseases in recovered patients.
- the loss of the sense of smell is a direct result of the virus infecting the olfactory neurons. It has been suggested that this may enable the virus to spread from the respiratory tract to the brain.
- Cells in the human brain express the ACE2 protein on their surface.
- ACE2 is also found on endothelial cells that line blood vessels. Infection of endothelial cells may allow the virus to pass from the respiratory tract to the blood and then across the blood-brain barrier into the brain. Once in the brain, replication of the virus may cause neurological disorders. Larger studies from China and France have also investigated the prevalence of neurological disorders in COVID-19 patients. These studies have shown that 36% of patients have neurological symptoms. Many of these symptoms were mild and include headache or dizziness that could be caused by a robust immune response.
- the virus is mainly spread during close contact and by small droplets produced when those infected cough, sneeze or talk. These small droplets may also be produced during breathing, but rapidly fall to the ground or surfaces and are not generally spread through the air over large distances. People may also become infected by touching a contaminated surface and then their face. The virus can survive on surfaces for up to 72 hours. It is most contagious during the first three days after onset of symptoms, although spread may be possible before symptoms appear and in later stages of the disease. The time from exposure to onset of symptoms is typically around five days, but may range from two to 14 days.
- the standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (RT- PCR) from a nasopharyngeal swab.
- the infection can also be diagnosed from a combination of symptoms, risk factors and a chest CT scan showing features of pneumonia.
- the method of treatment may comprise a step of administering the polypeptide of the invention to the subject.
- the skilled person will be able to determine by conventional methods the amount of the polypeptide of the invention that are able to exert a therapeutic effect on the patient.
- the polypeptide of the invention or the pharmaceutical composition of the invention may be administered once, but it may be administered multiple times.
- the polypeptide of the invention may be administered from three times daily to once every six months or longer.
- the administering may be on a schedule such as three times daily, twice daily, once daily, once every two days, once every three days, once weekly, once every two weeks, once every month, once every two months, once every three months and once every six months.
- the polypeptide of the invention or the pharmaceutical composition of the invention may also be administered continuously via a minipump.
- the polypeptide of the invention or the pharmaceutical composition of the invention may be administered via an oral, mucosal, buccal, intranasal, inhalable, intravenous, subcutaneous, intramuscular, parenteral, or topical route.
- the polypeptide of the invention may be administered locally or systemically.
- the polypeptide of the invention or the pharmaceutical composition of the invention may be administered once, at least twice or for at least the period of time until the condition is treated, palliated or cured.
- the polypeptide of the invention will generally be administered as part of a composition as described supra.
- the dosage of polypeptide of the invention will generally be in the range of 0.1-100 mg/kg, more preferably 0.5-50 mg/kg, more preferably 1-20 mg/kg, and even more preferably 1-10 mg/kg.
- the serum concentration of the polypeptide of the invention may be measured by any method known in the art.
- Example 1 Generation of binders specific for the ectodomain of hACE2 by phage display
- Single domain antibodies with specificity for human ACE2 were isolated from a combined naive llama phage display library using a combination of immobilised and solution phase antigen selection. Screening assays were initially carried out on recombinant protein.
- PBLs Peripheral blood lymphocytes from eight non-immunised llamas were isolated from 150 ml blood samples.
- RNA was isolated from PBLs using the RNeasy maxi kit (Qiagen).
- cDNA was synthesised from each llama using oligo-dT priming and Superscript III reverse transcriptase.
- dAb-encoding cDNA was amplified by PCR using specific primers, analysed to ensure presence of 400bp fragment and purified (Zymoclean). The resulting clean PCR product was cut by restriction enzyme digest (PST1 and NOT1) and ligated into M13 phage vector viral coat protein (pRL144). Multiple electroporations were performed into TGI E.
- TGI E. coli Phage with antibodies expressed as protein coat were amplified from TGI E. coli. Briefly, TGI cells were inoculated into 2TY media supplemented with glucose (2%)/ ampicillin (1 pg/ml) and cultured at 37 °C with agitation to an ODeoonm of 0.5 before addition of M13K07 helper phage. Cells were resuspended 40 min later into 2YT media supplemented with kanamycin and ampicillin (100 pg/70 pg/ml) and incubated at 30 °C overnight with agitation. Phage were purified using PEG based precipitation and titrated into TGI E. coli to determine PFUs/ml.
- Recombinant human ACE2 conjugated to a human IgG-Fc was immobilised on a Nunc immunotube at 1 pg/ml overnight at 4 °C before blocking with a 2% milk PBS solution. Phage were blocked in 2% milk PBS with 1 pg/ml of a Human IgG-Fc tagged protein included for further blocking (2ml) for 1 h before addition to the Human ACE2 coated immunotube. After 1 h at room temperature, the tube was washed 10 times using PBS 0.05% tween (4 ml/wash). Elution of specific phage was performed by addition of re-warmed trypsin (2 ml) to the tube and incubation at 37°C for 10-15 min. Eluted phage were amplified by reinfection into log phase TGI cells (5 ml) and plating out on Amp/Gluc agar plates. Titrations were performed to establish phage numbers and enrichment.
- Example 2 Generation of fusion proteins based on anti-hACE2 binders
- VHH hACE2-specific dAbs
- VHH hACE2-specific dAbs
- the plasmid vector is transiently transfected onto suspension Freestyle HEK293 using polyethylenimine (PEI), and onto ExpiCHO using Expifectamine transfection reagent. Transfected cells are cultured for 5 days in a shaker incubator at 37 °C, 8% CO2 to allow for protein secretion. Culture supernatant is filtered using 0,22pm filter units to remove large contaminants (cells and cellular debris).
- Fusion proteins are purified using an AKTATM pure system (GE Healthcare) using a HiTrap Blue HP 1 ml column (GE Healthcare). Briefly, columns are equilibrated with 5 column volumes of PBS pH 7.4. Supernatant is applied to the column at a flow rate of 1 mL/min. Following application of supernatant, the column is washed with 20 column volumes of PBS. Sample is then eluted from the column with 3 ml of PBS, 2M NaCl at 1 mL/min and is directly loaded onto 2 HiTrap 5 ml desalting columns, previously equilibrated in PBS, and is collected on a 96-well plate using a fraction collector unit. Proteins are characterised via SDS-PAGE under reducing and non-reducing conditions to assess molecular weight and purity.
- VHH The hACE2-specific dAbs (VHH) obtained in Example 1 were cloned in a protein expression vector using a murine IgKappa leader sequence. dAbs were fused to a Murine IgG 2A-Fc via a hinge spacer within the DNA coding vector. dAb-Fc conjugates were expressed as above in HEK293 or CHO cells and purified via HiTrap Protein A column (GE Healthcare) using an AKTATM pure system (GE Healthcare) following manufacturer’s instructions is sufficient. Desalting was performed as above using HiTrap 5ml desalting columns before SDS-PAGE visualisation again described above.
- the anti hACE2 dAb (VHH)-albumin based fusion proteins generated in Example 2 are characterised by ELISA to assess binding capacity to hACE2. Briefly, Nunc MaxiSorp flat- bottom 96-well plates are coated with 0.5 pg/ml of recombinant hACE2-Fc. As control, 0.5 pg/ml of B7H3-Fc peptides are coated at 1 pg/ml. Plates are blocked with a solution of 2% BSA in PBS for lh at RT. Antibodies (dAb (VHH)-albumin fusions) are incubated at a range of concentrations, diluted in 0.5% BSA, and allowed to bind for lh at room temperature.
- Non-specific interactions and un-bound fusion proteins are washed away by 4 PBS 0.05% Tween20 buffer washes. Bound fusion proteins are detected via anti-HSA-HRP conjugated secondary antibody. Un-bound fusion proteins are washed away using PBS 0.05% Tween20 buffer washes. Plates are incubated with substrate reagent (1-Step Ultra TMB, Thermo Scientific) and blocked with 1M H2SO4. Signal is acquired using a Varioskan plate reader at 450nm.
- Recombinant hACE2-Fc fusion proteins are immobilised on individual flow cells on a Series S CM5 sensor chip (GE Healthcare) previously functionalised with anti-human capture kit or protein A using a Biacore SPR instrument.
- HBS-P+ buffer is used as running buffer in all experimental conditions.
- Recombinant purified anti hACE2 dAb (VHH)-albumin-based fusion proteins (Example 2) at known concentrations are used as the ‘analyte’ and injected over the respective flow cells with 150 s contact time and 600 s dissociation at 30 m ⁇ /min of flow rate with a constant temperature of 25 °C.
- flow cell 1 is unmodified and used for reference subtraction.
- a ‘0 concentration’ sensorgram of buffer alone is used as a double reference subtraction to factor for drift. Data are fit to a 1:1 Langmuir binding model using local Rmax.
- the anti hACE2 dAb (VHH)-albumin-based fusion proteins generated in Example 2 are serially diluted from the mM to the pM range and the decreased concentrations fractions are incubated with hACE2 expressing cells and incubated for 30 min at 37 °C. Biotinylated recombinant soluble SI spike protein domain is then added at a constant concentration for 30 min at 37 °C. Cells are then washed with PBS to remove any unbound proteins and stained with Streptavidin conjugated to a fluorophore for 30 min at room temperature. After another PBS wash, cells are analysed for SI spike protein domain binding to ACE2 in the presence of recombinant therapeutics by flow cytometry.
- the enzymatic activity of active ACE2 in the presence of anti-hACE2 dAb (VHH)-albumin- based fusion proteins generated in Example 2 is measured by using Mca-APK(Dnp) (Enzo Life Science) as substrate in 96-well black microtiter plates.
- ACE2-Fc ACRO biosystems
- ACE2-Fc ACRO biosystems
- ACE2-Fc concentration 0.1 pg/ml
- VHH-albumin concentration 10 pg/mL
- the reaction is performed at room temperature for lh.
- Activity is measured as fluorescence intensity at 328 nm/393 nm (Ex/Em) wavelength at 1 -minute intervals using a Varioskan LEIX instrument (Thermo Scientific).
- Half maximal activity (t 1 ⁇ 2) (s) is calculated using non-linear fit in GraphPad Prism v8 (GraphPad software).
- the anti hACE2 dAb (VHH)-albumin-based fusion proteins generated in Example 2 are serially diluted to cover a broad range of concentrations. Each dilution is then mixed 1:1 with lentiviral vectors pseudotyped with SARS-CoV-2 spike protein to a final volume of 200 pL and incubated at 37 °C for 30 min-1 h.
- the lentiviral vectors also encode eGFP. Mixtures of fusion proteins and virus are then cultured onto hACE2 expressing cell line for 48-72 h. Viral titers are then quantified by eGFP expression in target cells and infectivity of all dilution is determined as a percentage of viral titers in the absence of the recombinant protein.
- Example 4 Generation of binders specific for the ectodomain of hACE2 by immunising Llama
- Single domain antibodies were expressed on phage after infection with M13K07.
- the phage library was panned for the presence of binders respectively on solid- phase ACE2 in wells of a microtitre plates or in solution with 100 nM biotinylated ACE2 in combination with streptavidin-coated magnetic beads.
- Example 5 Generation of fusion proteins based on anti-hACE2 binders and IgG Fc
- Anti-ACE2 dAbs (VHH) obtained in Example 4 were formatted into an IgG Fc as described in Example 2.
- hACE2-specific dAbs obtained in Example 4 were cloned in a protein expression vector using a murine IgKappa leader sequence. dAbs were fused to a Murine IgG 2A-Fc via a hinge spacer within the DNA coding vector.
- the dAb (VHH)-MuIgG2a Fc (dAb-Fc or VHH-Fc) conjugates were expressed as above in HEK293 or CHO cells and purified via HiTrap Protein A column (GE Healthcare) using an AKTATM pure system (GE Healthcare) following manufacturer’s instructions is sufficient. Desalting was performed as above using HiTrap 5ml desalting columns before SDS-PAGE visualisation again described above.
- Example 6 Characterisation of IgG-based fusion proteins based on anti-hACE2 binders (dAbs/VHHs)
- ACE2-Fc concentration 0.1 pg/ml
- VHH-IgG concentration 10 pg/mL
- the reaction was performed at room temperature for lh.
- Clones 55, 66, 72 and control clone 84, obtained from Example 5 were tested for neutralisation of viral infectivity using lentiviral vectors pseudotyped to express the SARS- CoV-2 spike glycoprotein from the WT (Wuhan) or B.1.1.7 variants.
- Selected anti-ACE2 clones, and the control ACE2-Fc protein were diluted in PBS to a concentration of 100 pg/mL. Each antibody was then mixed 1:1 with lentiviral vectors pseudotyped with SARS-CoV S glycoproteins normalised to 2.5 x 10 5 IU/ml, to a final volume of 200 pL and incubated at 37 °C for 30 minutes. Antibody -virus mixtures were then cultured for 72 h with 2.5 x 10 4 HEK-293T cells previously genetically engineered to express human ACE2 and TMPRSS2. Viral titers were then quantified by eGFP expression in target cells using MacsQuant cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the buffer only control.
- Results in Figure 8 show that clones 55, 66 and 72 efficiently neutralise the SARS-CoV-2 pseudoviruses tested, with neutralisation levels over 90% for clones 55 and 66 against both viruses and clone 72 against WT spike, and above 80% for clone 72 against B.l.1.7 spike expressing virus.
- Neutralisation levels were comparable to the ACE2-Fc receptor decoy molecule. No neutralisation was detected for the clone 84 which failed to show ACE2 binding in Figure 5 and SI competition in Figure 6.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2007441.5A GB202007441D0 (en) | 2020-05-19 | 2020-05-19 | Polypeptide |
GB2007441.5 | 2020-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021234383A1 true WO2021234383A1 (fr) | 2021-11-25 |
Family
ID=71135259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2021/051209 WO2021234383A1 (fr) | 2020-05-19 | 2021-05-19 | Anticorps à domaine unique contre hace2 et leur utilisation pour prévenir une infection par sars-cov-2 |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202007441D0 (fr) |
WO (1) | WO2021234383A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179546A1 (fr) * | 2022-03-21 | 2023-09-28 | 中国科学院微生物研究所 | Construction de nanocorps s43 et son utilisation |
WO2023235827A3 (fr) * | 2022-06-03 | 2024-01-04 | The Rockefeller University | Anticorps inhibant les coronavirus |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114989264B (zh) * | 2021-03-01 | 2023-07-21 | 中国医学科学院基础医学研究所 | 与SARS-CoV-2刺突蛋白特异性结合的多肽组合物及其制备方法与应用 |
CN113698487B (zh) * | 2021-08-16 | 2022-08-19 | 中国科学院微生物研究所 | 抗人ace2单克隆抗体及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2007441A (en) | 1977-09-23 | 1979-05-16 | Bryant Mfg Pty Ltd | Plug and socket connectors |
WO2004003019A2 (fr) | 2002-06-28 | 2004-01-08 | Domantis Limited | Ligand |
WO2005118642A2 (fr) | 2004-06-01 | 2005-12-15 | Domantis Limited | Compositions de medicaments, fusions et conjugues |
WO2006059105A2 (fr) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Conjugués protéiques non cytotoxiques |
WO2008096158A2 (fr) | 2007-02-08 | 2008-08-14 | Domantis Limited | Ligand |
WO2010059315A1 (fr) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Lieurs de sérum-albumine humaine et conjugués de ceux-ci |
WO2011006915A2 (fr) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Domaines variables uniques de liaison anti-albumine sérique améliorés |
WO2019204925A1 (fr) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Anticorps de liaison à l'albumine sérique pour extension de demi-vie réglable de produits biologiques |
-
2020
- 2020-05-19 GB GBGB2007441.5A patent/GB202007441D0/en not_active Ceased
-
2021
- 2021-05-19 WO PCT/GB2021/051209 patent/WO2021234383A1/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2007441A (en) | 1977-09-23 | 1979-05-16 | Bryant Mfg Pty Ltd | Plug and socket connectors |
WO2004003019A2 (fr) | 2002-06-28 | 2004-01-08 | Domantis Limited | Ligand |
WO2005118642A2 (fr) | 2004-06-01 | 2005-12-15 | Domantis Limited | Compositions de medicaments, fusions et conjugues |
WO2006059105A2 (fr) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Conjugués protéiques non cytotoxiques |
WO2008096158A2 (fr) | 2007-02-08 | 2008-08-14 | Domantis Limited | Ligand |
WO2010059315A1 (fr) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Lieurs de sérum-albumine humaine et conjugués de ceux-ci |
WO2011006915A2 (fr) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Domaines variables uniques de liaison anti-albumine sérique améliorés |
WO2019204925A1 (fr) * | 2018-04-24 | 2019-10-31 | National Research Council Of Canada | Anticorps de liaison à l'albumine sérique pour extension de demi-vie réglable de produits biologiques |
Non-Patent Citations (21)
Title |
---|
AGRAWAL ET AL., HUM VACCINE IMMUNOTHER, vol. 12, 2016, pages 2351 - 6 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 402 |
BINZ ET AL., NAT BIOTECH, vol. 23, 2005, pages 1257 - 68 |
BRINKMANNKONTERMANN, MABS, vol. 9, 2017, pages 182 - 212 |
CHEN YUNING ET AL: "ACE2-Targeting Monoclonal Antibody As A "Pan" 2 Coronavirus Blocker In Vitro and In A Mouse Model", BIORXIV, 12 November 2020 (2020-11-12), XP055837288, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.11.11.375972v1.full.pdf> [retrieved on 20210902], DOI: 10.1101/2020.11.11.375972 * |
CHOTHIALESK, J MOL BIOL, vol. 196, 1987, pages 901 - 17 |
DE VLIEGER DORIEN ET AL: "Single-Domain Antibodies and Their Formatting to Combat Viral Infections", ANTIBODIES, vol. 8, no. 1, 20 December 2018 (2018-12-20), pages 1, XP055811729, DOI: 10.3390/antib8010001 * |
DEYEV ET AL., NAT BIOTECH, vol. 21, 2003, pages 1486 - 92 |
DONNELLY ET AL., J GEN VIROL, vol. 82, 2001, pages 1027 - 41 |
HENIKOFFHENIKOFF, PROC NATL ACAD SCI USA, vol. 89, 1992, pages 10915 - 9 |
HOLT ET AL., PROTEIN ENG DES SEL, vol. 21, pages 283 - 8 |
JIANBO DONG ET AL: "Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity", EMERGING MICROBES & INFECTIONS, vol. 9, no. 1, 13 May 2020 (2020-05-13), pages 1034 - 1036, XP055735314, ISSN: 2222-1751, DOI: 10.1080/22221751.2020.1768806 * |
KABAT ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1991 |
LUPASGRUBER, ADVANCES IN PROTEIN CHEMISTRY, vol. 70, 2007, pages 37 - 8 |
MARKUS HOFFMANN ET AL: "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor", CELL, vol. 181, 5 March 2020 (2020-03-05), Amsterdam NL, XP055682148, ISSN: 0092-8674, DOI: 10.1016/j.cell.2020.02.052 * |
MOORE ET AL., J VIROL, vol. 78, 2004, pages 10628 - 35 |
NEEDLEMANWUNSCH, J MOL BIOL, vol. 48, 1970, pages 443 - 53 |
OU ET AL., BIORXIV 2020.03.15.991844; DOI: 10.1101/2020.03.15.991844, 2020 |
WANG ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 451, 2014, pages 208 - 14 |
WANG ET AL., J MED VIROL, 2020 |
WU ET AL., NAT BIOTECHNOL, vol. 25, 2007, pages 1290 - 7 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179546A1 (fr) * | 2022-03-21 | 2023-09-28 | 中国科学院微生物研究所 | Construction de nanocorps s43 et son utilisation |
WO2023235827A3 (fr) * | 2022-06-03 | 2024-01-04 | The Rockefeller University | Anticorps inhibant les coronavirus |
Also Published As
Publication number | Publication date |
---|---|
GB202007441D0 (en) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230293647A1 (en) | Polypeptide | |
WO2021234383A1 (fr) | Anticorps à domaine unique contre hace2 et leur utilisation pour prévenir une infection par sars-cov-2 | |
TWI793062B (zh) | Dll3及cd3抗體構築體 | |
CN107207611B (zh) | 针对流感血球凝集素的结合分子及其用途 | |
US20220403009A1 (en) | Multimeric coronavirus binding molecules and uses thereof | |
US20220017634A1 (en) | Engineered bispecific proteins | |
US20240059757A1 (en) | Antibodies against sars-cov-2 and methods of using the same | |
CA3053379A1 (fr) | Anticorps anti-tau et leurs procedes d'utilisation | |
EP3174903A1 (fr) | Construction d'anticorps monocaténaires bispécifiques avec distribution tissulaire améliorée | |
CA3141815A1 (fr) | Polypeptides anti-her2 et leurs methodes d'utilisation | |
US20220267415A1 (en) | Multimeric sars-cov-2 binding molecules and uses thereof | |
KR20220123072A (ko) | 신규 폴리펩티드 복합체 | |
WO2022271863A1 (fr) | Compositions de neutralisation de coronavirus et méthodes associées | |
WO2022031576A1 (fr) | Matériaux et procédés pour le biotransport multidirectionnel dans des agents virothérapeutiques | |
JP2023526274A (ja) | Sars-cov2中和単一ドメイン抗体構築物 | |
CN108472343B (zh) | 抗rsv融合前f蛋白的免疫球蛋白单可变结构域抗体 | |
WO2022253306A1 (fr) | Anticorps ciblant le coronavirus et son utilisation | |
CA3215698A1 (fr) | Liants de coronavirus pan-specifiques | |
WO2022095996A1 (fr) | Anticorps anti-sars-cov-2 et son utilisation | |
US20240174745A1 (en) | Antibody Constructs for CLDN18.2 and CD3 | |
RU2794359C2 (ru) | Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния | |
WO2022143815A1 (fr) | Anticorps neutralisant dirigé contre des épitopes du domaine de liaison au récepteur du nouveau coronavirus et son utilisation | |
WO2023288078A1 (fr) | Anticorps de coronavirus et leurs utilisations | |
WO2024068744A1 (fr) | Antiviraux dirigés contre le virus parainfluenza humain | |
CN117069831A (zh) | 广谱中和新冠病毒的纳米抗体、含其的融合蛋白及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21729599 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21729599 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12/07/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21729599 Country of ref document: EP Kind code of ref document: A1 |